NIR-II Fluorescence Imaging Protocols: Comprehensive Guide for In Vivo Lymphography and Angiography in Preclinical Research

Abstract

This article provides a comprehensive guide for researchers and drug development professionals on implementing and optimizing NIR-II (second near-infrared window) fluorescence imaging protocols for in vivo lymphography and angiography. It covers the foundational principles of NIR-II imaging, detailed methodological workflows for labeling and visualizing lymphatic and vascular systems, practical troubleshooting strategies for common experimental challenges, and validation techniques against gold-standard imaging modalities. The aim is to equip scientists with the knowledge to leverage the superior tissue penetration, high resolution, and low autofluorescence of NIR-II probes for advancing studies in oncology, inflammation, and vascular biology.

NIR-II Imaging Fundamentals: Unlocking Deep-Tissue Lymphatic and Vascular Visualization

Optical Properties: NIR-I vs. NIR-II

The near-infrared (NIR) spectrum is divided into windows based on photon scattering, absorption, and tissue autofluorescence. The second biological window (NIR-II, 1000-1700 nm) offers distinct advantages over the traditional first window (NIR-I, 700-900 nm).

Table 1: Comparative Optical Properties of NIR-I and NIR-II Windows

Property	NIR-I Window (700-900 nm)	NIR-II Window (1000-1700 nm)	Impact on Imaging
Tissue Scattering	Higher (∝ λ⁻⁰.²⁵ to λ⁻⁴)	Significantly Reduced (∝ λ⁻².⁴)	NIR-II enables deeper penetration and superior spatial resolution.
Water Absorption	Minimal	Peaks at ~1450 nm, low at 1000-1350 nm	Requires careful selection of sub-windows (e.g., NIR-IIa, 1300-1400 nm) for deep tissue.
Hemoglobin Absorption	Moderate	Lower than in NIR-I	Reduced background absorption improves signal-to-background ratio (SBR).
Tissue Autofluorescence	High from endogenous fluorophores (e.g., collagen, flavins)	Negligible	Drastically lowers background noise, enhancing contrast.
Typical Resolution Limit	~1-3 mm at 1 cm depth	Can be < 40 µm at 1 cm depth	Enables high-fidelity microvascular and structural imaging.
Maximum Penetration Depth	1-3 mm (high resolution)	5-10 mm+ (with high resolution)	Facilitates non-invasive whole-body imaging in small animals.

Key Sub-Windows within NIR-II:

• NIR-II (1000-1350 nm): Optimal balance of low scattering and minimal water absorption.
• NIR-IIa (1300-1400 nm): Further reduced scattering for highest resolution deep-tissue imaging.
• NIR-IIb (1500-1700 nm): Very low scattering but higher water absorption; useful with specialized detectors.

Detailed Experimental Protocols for NIR-II Imaging

Protocol 1: In Vivo NIR-II Lymphography in a Murine Model

Objective: To visualize and quantify lymphatic vessel architecture and drainage kinetics using NIR-II fluorescent probes.

Materials: See "The Scientist's Toolkit" below.

Procedure:

• Animal Preparation: Anesthetize the mouse (e.g., using 2% isoflurane). Secure the animal on a heated stage (37°C) to maintain body temperature.
• Probe Administration: Using a 31G insulin syringe, perform an intradermal injection of 10-20 µL of NIR-II fluorophore (e.g., IRDye 12.5 µM in PBS) into the distal tail or paw pad.
• Image Acquisition:
  • Position the animal under the NIR-II imaging system.
  • Use a 1500 nm short-pass filter with an InGaAs camera for NIR-II (1000-1500 nm) imaging.
  • Acquire time-series images immediately post-injection (e.g., 1 frame/sec for 5 min, then 1 frame/min for 60 min).
  • Maintain consistent laser power (e.g., 100 mW/cm²) and exposure time (e.g., 50-200 ms).
• Data Analysis:
  • Use region-of-interest (ROI) analysis to plot fluorescence intensity over time in collecting lymphatic vessels and draining lymph nodes.
  • Calculate metrics: Drainage Velocity (mm/sec), Contrast-to-Noise Ratio (CNR), and Vessel Diameter.

Protocol 2: NIR-II Micro-Angiography for Vascular Hemodynamics

Objective: To achieve high-resolution, real-time imaging of blood flow dynamics and vascular permeability.

Procedure:

• Circulating Blood Pool Labeling: Administer 100 µL of an NIR-II-emitting contrast agent (e.g., Ag₂S quantum dots, carbon nanotubes, or organic dye-protein complexes) via intravenous tail vein injection.
• Dynamic Imaging:
  • For cerebral angiography, perform a craniotomy or use a thinned-skull preparation.
  • Initiate high-speed imaging (≥ 10 frames/sec) immediately after injection to capture the first-pass bolus.
  • Switch to slower acquisition (1-2 frames/sec) for steady-state imaging.
• Functional Analysis:
  • Blood Flow Velocity: Track individual particles in capillaries using particle tracking algorithms.
  • Vascular Permeability: Following agent clearance from blood pool, monitor signal extravasation in tissues over hours, calculating permeability coefficients.
  • 3D Angiography: Perform raster-scanning across the tissue to reconstruct 3D vascular architecture.

Visualization: NIR-II Imaging Advantage & Workflow

NIR-II vs NIR-I Imaging Advantage Pathway

NIR-II In Vivo Imaging Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for NIR-II Lymphography/Angiography Research

Item	Function & Rationale	Example Products/Types
NIR-II Fluorophores	Emit light in the NIR-II window for deep-tissue, high-contrast imaging.	Organic Dyes (CH-4T, IR-1061), Quantum Dots (Ag₂S, PbS), Single-Wall Carbon Nanotubes, Lanthanide Nanoparticles.
NIR-II Imaging System	Detects NIR-II photons with high sensitivity and low noise.	InGaAs Camera (cooled), 808 nm/980 nm Laser Source, Long-pass (>1000 nm) or Short-pass (<1500 nm) Filters.
Animal Preparation Suite	Ensures humane, consistent animal physiology during imaging.	Isoflurane Anesthesia System, Heated Stage, Surgical Tools for cannulation or craniotomy.
Image Analysis Software	Quantifies dynamic fluorescence signals and derives pharmacokinetic parameters.	ImageJ (with NIR-II plugins), MATLAB, Living Image Software, Custom Python Scripts.
Reference NIR-I Dye	Provides direct comparison to traditional imaging within the same study.	Indocyanine Green (ICG), IRDye 800CW.
Phantom Materials	Calibrates system performance and validates resolution claims.	Agarose Intralipid Phantoms, Multi-layer Tissue-Simulating Slides.

Core Principles of NIR-II Fluorescence for Dynamic Vascular and Lymphatic Imaging

Within the broader thesis on advancing in vivo optical imaging, this document establishes the core photophysical principles and procedural frameworks for NIR-II (1000-1700 nm) fluorescence imaging. This modality is central to developing robust lymphography and angiography protocols, offering superior resolution and penetration depth for dynamic vascular and lymphatic system analysis in preclinical research and therapeutic development.

Core Photophysical Principles

The advantages of NIR-II imaging stem from reduced photon scattering and minimized tissue autofluorescence in the 1000-1700 nm window compared to visible and NIR-I (700-900 nm) light.

Table 1: Quantitative Comparison of Optical Windows for In Vivo Imaging

Parameter	Visible (400-700 nm)	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)
Tissue Scattering	Very High	High	Low
Autofluorescence	Very High	Moderate	Negligible
Absorption by Water & Hemoglobin	High	Moderate	Low
Typical Penetration Depth	< 1 mm	1-3 mm	3-8 mm
Theoretical Resolution at 3 mm Depth	~15 µm	~10 µm	~5 µm

Research Reagent Solutions Toolkit

Table 2: Essential Materials for NIR-II Vascular/Lymphatic Imaging

Item	Function & Rationale
NIR-II Fluorophores (e.g., Ag2S QDs, SWCNTs, organic dyes like IR-1061)	Emit fluorescence in the 1000-1700 nm range; serve as contrast agents.
PBS (pH 7.4)	Universal vehicle for fluorophore dilution and injection.
Indocyanine Green (ICG)	FDA-approved NIR-I dye for benchmark comparisons.
Methylene Blue (1%)	Visualizes lymphatic vessels for guidance during intralymphatic injection.
Heparinized Saline	Prevents catheter clogging during surgical cannulation procedures.
Isoflurane/Oxygen Mix	Standard and stable anesthetic for longitudinal imaging sessions.
Sterile Ophthalmic Ointment	Prevents corneal desiccation during prolonged anesthesia.
Homeothermic Heating Pad	Maintains animal core temperature, ensuring hemodynamic stability.
NIR-II-Optimized Imaging System	Includes laser excitation (808 nm or 980 nm), InGaAs or SWIR cameras, and appropriate long-pass filters (>1000 nm).

Application Notes & Detailed Protocols

Protocol 4.1: Systemic Angiography for Vascular Hemodynamics

Objective: To visualize real-time systemic blood flow and quantify vascular parameters.

• Animal Preparation: Anesthetize mouse/rat with isoflurane (2-3% induction, 1-2% maintenance). Secure in a supine position on a heating pad.
• Tail Vein Cannulation: Warm tail with a heat lamp for 1-2 min. Insert a 30G insulin syringe into the lateral tail vein.
• Fluorophore Administration: Inject 100-200 µL of NIR-II fluorophore (e.g., 100 µM IR-1061 in PBS) as a rapid bolus.
• Image Acquisition: Start acquisition (5-10 frames/sec) immediately before injection. Use 808 nm laser excitation (20-50 mW/cm²) and collect signal with a 1200 nm long-pass filter.
• Data Analysis: Use time-intensity curves to derive metrics: Time-to-Peak (TTP), Cerebral Blood Flow (CBF) index, and vessel sharpness.

Protocol 4.2: Intralymphatic Injection for Lymphography

Objective: To specifically label and track lymphatic vessel architecture and drainage kinetics.

• Lymphatic Identification: Inject 5-10 µL of 1% methylene blue subcutaneously into the paw or tail tip. Allow it to drain for 2-5 min to reveal superficial collecting lymphatic vessels.
• Surgical Exposure: Make a small skin incision under a dissection microscope to expose the blue-stained vessel.
• Micro-cannulation: Using a micromanipulator, cannulate the vessel with a bevelled glass micropipette (tip diameter ~80 µm) filled with heparinized saline.
• NIR-II Tracer Injection: Slowly infuse 20-40 µL of NIR-II fluorophore (e.g., 50 nM Ag2S QDs) over 30 seconds.
• Dynamic Imaging: Acquire images at 1-2 frames/sec for 10-20 minutes to track lymphatic propulsion, valve function, and drainage to lymph nodes.

Experimental Workflow and Pathway Diagrams

Workflow for NIR-II Imaging Protocols

Principles of Superior NIR-II Image Contrast

This document details application notes and protocols within the broader thesis research on optimizing NIR-II (1000-1700 nm) fluorescence imaging for dynamic in vivo lymphatic and blood vascular system assessment. The distinct anatomical and physiological characteristics of these two circulatory systems, summarized below, mandate tailored imaging agent design, administration routes, and acquisition protocols to achieve high target-to-background ratios (TBR) and accurate physiological quantification.

Comparative Anatomy & Physiology: Implications for Imaging

The structural and functional differences between blood and lymphatic vasculature fundamentally influence imaging strategy.

Table 1: Key Anatomical & Physiological Comparisons

Feature	Blood Vasculature	Lymphatic Vasculature
Circuit Type	Closed, high-pressure, circular.	Open-ended, low-pressure, one-way.
Vessel Wall Structure	Endothelium + thick smooth muscle/elastic layers (arteries); Endothelium + pericytes (capillaries).	Endothelium + thin or absent smooth muscle; Overlapping oak leaf-shaped cells.
Fluid Transported	Blood (plasma, cells, proteins).	Lymph (interstitial fluid, cells, lipids, antigens).
Flow Drivers	Cardiac output; arterial pressure.	Intrinsic lymphatic pumping; extrinsic compression.
Typical Access Points	Intravenous (IV) injection; intra-arterial.	Intradermal (ID), subcutaneous (SC), or interstitial injection.
Primary Imaging Target	Vascular lumen (angiography), endothelial surface, leakiness (permeability).	Initial lymphatic capillaries, collecting vessels, lymph nodes.
Key Quantitative Metrics	Perfusion rate, velocity, vessel diameter, permeability (Ktrans).	Lymphatic propulsion frequency, packet velocity, vessel drainage pattern, lymph node accumulation.

Table 2: NIR-II Imaging Agent Requirements by System

Parameter	Angiography (Blood)	Lymphography (Lymphatics)
Ideal Hydrodynamic Diameter	< 6 nm for extravasation studies; 10-150 nm for prolonged intravascular circulation.	10-100 nm optimal for lymphatic capillary uptake; < 10 nm may drain to blood.
Optimal Injection Volume/Conc.	Small volume (50-200 µL), high concentration for bolus tracking.	Larger volume (20-100 µL), moderate concentration to drive interstitial flow.
Kinetics	Fast (seconds to minutes).	Slow (minutes to hours).
Critical Agent Property	High quantum yield in NIR-II; stability in blood; low non-specific binding.	Specific uptake by lymphatic endothelial cells (e.g., via LYVE-1 or VEGFR-3 targeting) or optimal size-based drainage.

Experimental Protocols

Protocol 3.1: Dynamic NIR-II Lymphography in a Murine Hindlimb

Objective: To visualize and quantify lymphatic drainage and propulsion kinetics. Reagents: NIR-II fluorescence agent (e.g., PEGylated single-wall carbon nanotubes [SWCNTs] or Ag₂S quantum dots, 20-40 nm diameter). Equipment: NIR-II fluorescence imaging system with 808 nm or 980 nm excitation laser, InGaAs camera, isoflurane anesthesia setup, heating pad.

• Animal Preparation: Anesthetize mouse (e.g., C57BL/6) with isoflurane (2-3% induction, 1-2% maintenance). Place in supine position on a heating pad (37°C). Depilate the hindlimb.
• Agent Administration: Using a 30G insulin syringe, perform an intradermal injection of 30 µL of NIR-II agent (≈ 50 µM) into the distal footpad.
• Image Acquisition: Begin continuous imaging (100-500 ms exposure) immediately post-injection. Acquire sequential frames for 20-30 minutes. Maintain anatomical landmarks in frame.
• Data Analysis:
  • Vessel Identification: Trace collecting lymphatic vessels.
  • Kinetic Quantification: Use kymograph analysis along vessel length to calculate lymphatic packet propulsion frequency (packets/min) and velocity (µm/sec).
  • Drainage Mapping: Record time-to-drain to popliteal and iliac lymph nodes.

Protocol 3.2: NIR-II Fluorescence Angiography for Cerebral Blood Flow

Objective: To map cerebral vasculature and measure relative blood flow velocity. Reagents: FDA-approved indocyanine green (ICG) or novel NIR-II molecular dye (e.g., CH-4T). Equipment: As in 3.1, with a stereotaxic frame for head fixation, and surgical tools for cranial window preparation if required.

• Animal/Sample Preparation: Anesthetize and secure mouse in stereotaxic frame. Perform a craniotomy to create a cranial window if imaging through the intact skull provides insufficient resolution. Keep the dura mater moist with saline.
• Agent Administration: Place a catheter in the tail vein. Prepare a bolus of 100 µL of ICG (100 µM) or NIR-II dye.
• Image Acquisition: Set imaging system to high speed (50-100 ms exposure). Initiate recording and immediately administer the dye bolus via the IV catheter. Record for 2-5 minutes.
• Data Analysis:
  • Angiogram Generation: Generate a maximum intensity projection (MIP) from the image stack.
  • Velocity Calculation: Use temporal color-coding (TiCo) analysis or line-scan perfusion analysis to visualize flow direction and calculate relative velocity in selected vessels.
  • Vessel Diametry: Measure full-width at half-maximum (FWHM) intensity profiles across vessels.

Visualizations

Title: NIR-II Imaging Protocol Workflow Decision Tree

Title: Key Lymphatic Uptake Signaling Pathways

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Lymph/Angiography Research

Item	Function/Description	Example (for reference)
NIR-II Fluorophores	Emit light in the 1000-1700 nm range for deep-tissue, high-resolution imaging.	ICG, PEGylated SWCNTs, Ag2S Quantum Dots, Organic Dyes (CH-4T, IR-1061).
Targeting Ligands	Conjugated to fluorophores to enhance specificity for lymphatic or vascular markers.	Anti-LYVE-1 antibody, VEGF-C protein, RGD peptides (for angiogenic endothelium).
Size-Tuning Matrices	Polymers (e.g., PEG) or coatings to precisely control hydrodynamic diameter for lymphatic drainage.	PEG5k-COOH, phospholipid-PEG.
Dynamic Imaging Software	For capturing high-frame-rate sequences and analyzing spatiotemporal kinetics.	LI-COR PE, MATLAB with custom scripts, ImageJ with PIV plugin.
Anesthesia & Delivery System	Precise gas anesthesia for stable, long-term imaging; micro-injection pumps for consistent bolus.	Isoflurane vaporizer, 30G insulin syringes, tail vein catheters.
In Vivo Imaging System	Integrated excitation lasers (808/980 nm), sensitive InGaAs cameras, and spectral filters.	Custom-built or commercial NIR-II imaging platforms.

This application note provides a detailed overview of four major classes of NIR-II (1000-1700 nm) fluorophores within the context of developing advanced protocols for in vivo lymphography and angiography. The superior tissue penetration and reduced scattering in the NIR-II window enable high-resolution, deep-tissue imaging of vascular and lymphatic structures, critical for preclinical research in oncology, cardiovascular diseases, and drug development. Selecting the appropriate fluorophore requires balancing optical properties, biocompatibility, and functionalization potential.

NIR-II Fluorophore Types, Properties, and Quantitative Comparison

Table 1: Comparative Properties of Major NIR-II Fluorophore Classes

Property	Quantum Dots (QDs)	Single-Walled Carbon Nanotubes (SWCNTs)	Organic Dyes	Lanthanide-Doped Nanoparticles (LnNPs)
Core Composition	PbS, Ag2S, InAs, CdHgTe	Carbon lattice (n,m) chirality	Polymethine, donor-acceptor-donor	NaYF4, CaF2 host; Nd3+, Er3+, Yb3+ dopants
Emission Range (nm)	1000 - 1600	1000 - 1400 (E11)	900 - 1300	1000 - 1600
Absorption Range	Broad, size-tunable	Broad, chirality-dependent	Narrow, structure-dependent	Multiple narrow ion peaks
Quantum Yield (%)	5 - 15 (in water)	0.1 - 1.5	0.1 - 10	0.1 - 10 (in core-shell)
Extinction Coeff. (M⁻¹cm⁻¹)	~10⁶ - 10⁷	~10⁷ (per mg/L)	10⁴ - 10⁵	Low (sensitive to excitation)
Stokes Shift (nm)	100 - 300	>200	10 - 30	>200 (anti-Stokes possible)
Excitation Source	808 nm, 980 nm lasers	808 nm, 980 nm lasers	~808 nm, ~980 nm lasers	808 nm, 980 nm, 1530 nm lasers
Biodegradability	Poor (inorganic core)	Non-biodegradable	Good (small molecule)	Poor (inorganic matrix)
Functionalization	PEG, peptides, antibodies	PEG, phospholipids, DNA, antibodies	Carboxyl, NHS ester, biotin	Silica/Polymer coating, antibody conjugation
Key Advantages	Bright, tunable, photostable	Deep penetration, photostable	Rapid clearance, clinical translation potential	Long lifetime, no autofluorescence, multiplexing
Key Limitations	Potential heavy metal toxicity	Low QY, complex purification	Low brightness, rapid photobleaching	Low brightness, complex synthesis

Selection Criteria for Lymphography and Angiography

• Brightness & Penetration: For deep-tissue angiography (e.g., imaging cerebral or tumor vasculature), brightness (QY * ε) and emission >1300 nm are paramount. SWCNTs and certain QDs are preferred.
• Circulation Half-life & Clearance: For dynamic contrast-enhanced angiography, organic dyes offer rapid clearance. For long-term lymphatic mapping, PEGylated QDs or LnNPs with prolonged circulation are ideal.
• Biocompatibility & Toxicity: For potential clinical translation, heavy-metal-free organic dyes and certain LnNPs (e.g., CaF2 host) are favored over Cd/Pb-based QDs.
• Functionalization: For targeted lymphography of specific immune cells or lymphatic endothelial markers, fluorophores with facile conjugation chemistry (e.g., carboxylated QDs, NHS-dye esters) are required.
• Multiplexing: LnNPs, with their narrow excitation peaks and long lifetimes, enable time-gated multiplexing to distinguish multiple lymphatic basins simultaneously.

Detailed Experimental Protocols

Protocol 4.1: Synthesis and PEGylation of Ag2S Quantum Dots for Angiography

Objective: To synthesize biocompatible, water-soluble Ag2S QDs emitting at 1200 nm for high-resolution in vivo vascular imaging.

Materials:

• Silver nitrate (AgNO3), Sodium sulfide (Na2S·9H2O), 3-Mercaptopropionic acid (MPA), 1-Octadecene (ODE).
• Methoxy-PEG-thiol (MW 5000 Da), Phosphate Buffered Saline (PBS, pH 7.4), Dialysis tubing (MWCO 10kDa).

Procedure:

• Synthesis: In a three-neck flask under N2, heat 10 mL ODE to 120°C. Inject a solution of 0.1 mmol AgNO3 and 0.3 mmol MPA in 2 mL ODE. After 10 min, rapidly inject 0.05 mmol Na2S in 1 mL deionized water. React at 120°C for 1 hour. Cool to room temperature.
• Purification: Precipitate QDs with ethanol, centrifuge (12,000 rpm, 10 min), and redisperse in chloroform.
• Phase Transfer: Mix the QD chloroform solution with an aqueous solution of 50 mg mPEG-SH in 5 mL PBS. Stir vigorously overnight. Allow phases to separate; collect the aqueous phase containing PEGylated QDs.
• Final Purification: Dialyze the aqueous solution against PBS for 48 hours (water changed 6 times) to remove excess PEG and by-products. Sterilize by 0.22 µm filtration. Store at 4°C protected from light. Characterize by UV-Vis-NIR spectroscopy, photoluminescence, and DLS.

Protocol 4.2:In VivoNIR-II Lymphography Using a Clinical Organic Dye

Objective: To perform real-time imaging of lymphatic drainage and sentinel lymph node mapping in a murine model using the FDA-approved dye Indocyanine Green (ICG).

Materials:

• ICG (lyophilized powder), Sterile saline, 29G insulin syringe.
• NIR-II imaging system (e.g., InGaAs camera, 808 nm laser illumination, 1000 nm longpass filter).
• Anesthetized mouse (e.g., Balb/c, dorsal aspect shaved).

Procedure:

• Dye Preparation: Reconstitute ICG in sterile saline to a concentration of 0.5 mg/mL. Protect from light and use within 2 hours.
• Animal Preparation: Anesthetize mouse with isoflurane (2-3% in O2). Place mouse in prone position on a heated stage (37°C) under the NIR-II camera.
• Injection: Intradermally inject 10 µL (5 µg) of ICG solution into the distal footpad of the hind limb using the insulin syringe.
• Image Acquisition:
  • Set laser power to 100 mW/cm², camera integration time to 100-200 ms.
  • Begin acquisition immediately post-injection. Capture images continuously at 5 frames per second for the first 2 minutes, then every 10 seconds for 20 minutes.
  • Maintain consistent imaging geometry and settings across all animals.
• Data Analysis: Use imaging software to quantify signal intensity over time in the primary draining lymph node (popliteal). Generate time-intensity curves to calculate parameters like time-to-peak and clearance rate.

Protocol 4.3: Conjugation of Targeting Ligands to Lanthanide Nanoparticles

Objective: To conjugate anti-LYVE-1 antibodies to PEG-coated NaYF4:Nd@NaYF4 nanoparticles for targeted lymphatic endothelial imaging.

Materials:

• PEG-coated NaYF4:Nd@NaYF4 NPs (COOH surface), Anti-mouse LYVE-1 antibody, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS).
• 2-(N-morpholino)ethanesulfonic acid (MES) buffer (0.1 M, pH 6.0), PBS (pH 7.4), Bovine Serum Albumin (BSA), Zeba Spin Desalting Columns (7K MWCO).

Procedure:

• NP Activation: Dilute 1 mL of NPs (1 mg/mL in MES buffer) with 4 mL MES. Add 50 µL of fresh EDC solution (10 mg/mL in MES) and 50 µL of NHS solution (10 mg/mL in MES). React on a rotator for 20 min at room temperature.
• Purification: Immediately pass the reaction mixture through a Zeba column pre-equilibrated with PBS (pH 7.4) to remove excess EDC/NHS. Collect the activated NPs.
• Conjugation: Add 100 µg of anti-LYVE-1 antibody to the activated NP solution. Incubate on a rotator at 4°C for 12-16 hours.
• Quenching & Blocking: Add 100 µL of 1 M glycine to quench unreacted sites. Incubate for 30 min. Then add BSA to a final concentration of 1% (w/v) and incubate for 1 hour to block non-specific binding sites.
• Final Purification: Purify the conjugate via size-exclusion chromatography or ultracentrifugation (100k MWCO, 14,000 rpm, 20 min, washed 3x with PBS). Resuspend in sterile PBS with 0.1% BSA. Characterize conjugation efficiency via SDS-PAGE or fluorescence correlation spectroscopy.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for NIR-II Lymphography/Angiography Experiments

Item	Function/Benefit	Example Product/Catalog #
Indocyanine Green (ICG)	Clinically available NIR-I/II dye for proof-of-concept dynamic imaging.	Sigma-Aldrich, I2633
CH1055-PEG Dye	High-performance, water-soluble organic NIR-II dye with high QY.	Lumiprobe, 2105
PbS Quantum Dots (1200 nm)	Bright, commercially available QDs for deep-tissue angiography studies.	NN-Labs, NIR12-PBS-TOL-1
(6,5) Chirality SWCNTs	Semiconducting SWCNTs with defined 990 nm emission for consistent imaging.	NanoIntegris, IsoSol-S6.5
NaYF4:Yb,Er@NaYF4	Upconverting nanoparticle core for synthesizing NIR-II emitting LnNPs.	Sigma-Aldrich, 900458
Methoxy-PEG-Thiol (5kDa)	For surface functionalization and imparting stealth properties to nanoparticles.	Creative PEGWorks, PSB-001
EZ-Link NHS-PEG4-Biotin	Facilitates conjugation and subsequent streptavidin-based targeting strategies.	Thermo Fisher, A39259
Anti-mouse LYVE-1 Antibody	Targets lymphatic vessel endothelial hyaluronan receptor-1 for specific lymphography.	R&D Systems, AF2125
Matrigel (Growth Factor Reduced)	For creating in vivo angiogenesis models (e.g., plug assay).	Corning, 356231
In Vivo Imaging Software	For quantification, 3D reconstruction, and pharmacokinetic analysis of NIR-II data.	Bruker MI SE, PerkinElmer Living Image

Visualizations

Decision Workflow for NIR-II Fluorophore Selection

NIR-II Lymphography Imaging Workflow

This document outlines the critical equipment and protocols for conducting in vivo NIR-II (1000-1700 nm) fluorescence imaging, a core methodology for the broader thesis on developing high-sensitivity, deep-tissue lymphography and angiography protocols. Optimal setup is paramount for visualizing deep-seated lymphatic vessels and microvasculature with superior spatial and temporal resolution compared to traditional NIR-I imaging.

Core Equipment Specifications & Selection

The performance of NIR-II imaging is dictated by the synergistic integration of three core components: the excitation source, the emission filtration, and the detection camera.

Table 1: NIR-II Laser Specifications for Angiography/Lymphography

Parameter	Optimal Specification	Rationale for Protocol
Wavelength	808 nm, 980 nm, or 1064 nm	Matches common NIR-II fluorophore excitation (e.g., IRDye800CW, ICG, SWCNTs, quantum dots). 808 nm offers deeper penetration than visible light. 1064 nm reduces tissue scattering/autofluorescence.
Power Density	50 - 200 mW/cm² (in vivo)	Must balance sufficient signal excitation with strict adherence to ANSI laser safety limits for skin exposure (e.g., ~330 mW/cm² @ 808 nm).
Modulation	Continuous Wave (CW) or Pulsed	CW is standard for most fluorescence studies. Pulsed lasers enable time-gated imaging to suppress autofluorescence.
Beam Profile	Top-hat, uniform illumination	Essential for quantitative comparison of signal intensity across the imaging field.

Table 2: NIR-II Camera System Comparison

Camera Type	Detection Range (nm)	Quantum Efficiency (QE)	Cooling Temperature	Key Advantage	Consideration for Protocols
InGaAs FPA	900-1700	60-85% (peaks ~1550 nm)	-70°C to -100°C (deep)	High QE, standard for NIR-II. Excellent for dynamic imaging.	High cost. Pixel resolution typically 320x256 or 640x512.
sCMOS with NIR-II Extender	400-1000 (extended)	~40% @ 1000nm, <1% >1100nm	-20°C to -45°C	Lower cost, high resolution (2048x2048).	Effective only for NIR-IIa (1000-1400 nm) with specific coatings.
HgCdTe (MCT)	800-2500	50-70%	-120°C (cryogenic)	Broadest spectral range.	Very high cost, complex maintenance. Often over-specified for bio-imaging.

Table 3: Essential Filter System Components

Component	Type/Example	Function in Optical Path
Excitation Filter	Bandpass (e.g., 785/10 nm, 980/10 nm)	Placed after laser; cleanses laser line, removes sideband emission.
Beam Splitter/Dichroic Mirror	Longpass (e.g., LP 1000 nm, LP 1200 nm)	Reflects laser light to sample, transmits longer-wavelength NIR-II emission to camera. Critical cutoff choice defines detection window.
Emission Filter	Longpass or Bandpass (e.g., LP 1250 nm, BP 1000/40 nm)	Final barrier before camera; blocks any residual scattered laser light and short-wavelength autofluorescence.

Diagram Title: NIR-II Imaging Optical Path

Integrated Experimental Protocols

Protocol 3.1: System Calibration & Sensitivity Measurement

Objective: Establish the system's limit of detection (LOD) for quantitative lymphography.

• Prepare Fluorophore Dilutions: Serially dilute a known NIR-II fluorophore (e.g., IR-12N) in PBS or serum across a range from 1 µM to 1 pM.
• Imaging Parameters: Set laser power to 100 mW/cm² (ensure safety compliance). Set camera integration time to 100-500 ms. Use a dichroic LP1000nm and emission LP1250nm filter.
• Acquire Images: Place 10 µL droplets of each dilution on a glass slide. Acquire images in triplicate.
• Data Analysis: Measure mean signal intensity (counts) and standard deviation of background (no fluorophore). Calculate Signal-to-Noise Ratio (SNR). LOD = Concentration where SNR ≥ 3.

Protocol 3.2: In Vivo NIR-II Lymphography in Murine Hind Limb

Objective: Visualize and quantify lymphatic drainage kinetics.

• Animal Preparation: Anesthetize mouse (e.g., 2% isoflurane). Shave hind limb. Secure in prone position on a 37°C heated stage.
• Tracer Injection: Intradermally inject 10 µL of 100 µM ICG (or comparable NIR-II agent) into the footpad using a 31-gauge insulin syringe.
• Dynamic Image Acquisition:
  • Camera: InGaAs, 50 ms integration time, 2 frames per second for 10 minutes.
  • Laser: 808 nm CW laser, 80 mW/cm² at the sample plane.
  • Filters: 785/10 nm exciter, LP1000 nm dichroic, LP1250 nm emitter.
• Data Processing: Use ROI analysis to plot fluorescence intensity vs. time in popliteal lymph node. Calculate drainage velocity (pixels/sec) and time-to-peak.

Diagram Title: NIR-II Lymphography Experimental Workflow

Protocol 3.3: NIR-II Angiography for Tumor Vascularure

Objective: Characterize tumor vessel morphology and perfusion.

• Tumor Model: Use a mouse with a subcutaneous tumor (~200-500 mm³).
• Tracer Administration: Intravenously inject 100 µL of 200 µM FDA-approved ICG via tail vein.
• Image Acquisition: Begin high-speed imaging 5 seconds post-injection.
  • Settings: 50 ms integration, 5 fps for 60s, then 1 fps for 600s.
  • Filters: 808 nm laser, LP1200 nm dichroic, BP1300/40 nm emission filter to maximize contrast.
• Analysis: Generate maximum intensity projection (MIP). Quantify parameters: vessel diameter, density, tortuosity, and perfusion halftime from time-intensity curves.

The Scientist's Toolkit: Key Research Reagent Solutions

Item Name	Supplier Examples	Function in NIR-II Imaging
Indocyanine Green (ICG)	PULSION, Diagnostic Green	FDA-approved clinical fluorophore; acts as NIR-II emitter (~1300 nm) for angiography/lymphography.
IRDye 800CW	LI-COR Biosciences	Common targeting dye-conjugate for antibody/NIR-II probes; excites at ~780 nm.
PEGylated Single-Walled Carbon Nanotubes (SWCNTs)	NanoIntegris, Sigma-Aldrich	High-quantum-yield NIR-II fluorophores with tunable emission; used for long-term tracking.
Ag₂S or Ag₂Se Quantum Dots	NN-Labs, Ocean NanoTech	Bright, biocompatible NIR-II probes with narrow emission bands for multiplexing.
Matrigel Matrix	Corning	Used for creating window chambers or embedding tumors for longitudinal vascular imaging.
Isoflurane Anesthesia System	VetEquip, SomnoSuite	Provides stable, long-term anesthesia essential for in vivo dynamic imaging sessions.
NIR-II Calibration Standards	Thorlabs (e.g., NIST-traceable sources)	For validating camera linearity, uniformity, and absolute intensity measurements.

Step-by-Step Protocols for Robust NIR-II Lymphography and Angiography In Vivo

Probe Preparation and Functionalization for Targeted vs. Non-Targeted Imaging

This document provides detailed application notes and protocols for the preparation and functionalization of imaging probes, framed within a broader thesis focused on developing standardized protocols for NIR-II (1000-1700 nm) lymphography and angiography. The ability to visualize deep-tissue lymphatic and vascular structures with high spatial and temporal resolution using NIR-II fluorescence has revolutionized preclinical research. The choice between targeted and non-targeted probes dictates the experimental design, functionalization strategy, and ultimate biological application. These protocols are designed for researchers, scientists, and drug development professionals aiming to implement or optimize NIR-II imaging in their work.

Core Principles and Quantitative Comparison

Targeted imaging probes are conjugated with biological ligands (e.g., antibodies, peptides) to bind specific molecular markers, enabling the visualization of pathological processes like inflammation or tumor angiogenesis. Non-targeted probes, such as dynamic contrast agents, rely on passive accumulation (e.g., EPR effect) or inherent circulation kinetics to outline vasculature and lymphatic drainage patterns.

Table 1: Key Characteristics of Targeted vs. Non-Targeted NIR-II Probes

Parameter	Targeted Probes	Non-Targeted Probes
Primary Imaging Goal	Molecular event detection (e.g., VEGFR-2 expression)	Anatomical & hemodynamic mapping (vessel integrity, flow)
Typical Conjugation	Covalent (amide, click chemistry) to antibodies, peptides	Often anionic coating (PEG, polymers) for stability
Common NIR-II Cores	Single-Walled Carbon Nanotubes (SWCNTs), Ag₂S QDs, Lanthanide NPs	ICG derivatives, PbS/CdSe QDs, conjugated polymers
Injection-to-Imaging Time	Hours to Days (for target accumulation)	Seconds to Minutes (first-pass imaging)
Key Quantitative Metric	Target-to-Background Ratio (TBR)	Signal-to-Noise Ratio (SNR), Circulation Half-life (t₁/₂β)
Typical TBR/SNR in NIR-II*	TBR: 3.5 - 8.5	SNR: 15 - 40 (for major vessels)
Primary Application in Thesis	Tumor angiogenesis (VEGFR/αvβ3 targeting), Lymph node metastasis	Lymphatic trunk mapping, Cerebral & Cardiac angiography

*Representative ranges from recent literature (2023-2024).

Detailed Experimental Protocols

Protocol 3.1: Synthesis and PEGylation of Ag₂S Quantum Dots (Non-Targeted Base Probe)

Objective: To produce water-soluble, stable Ag₂S QDs with emission in the NIR-IIb (1500-1700 nm) window for high-contrast angiography. Materials: Silver nitrate (AgNO₃), Sodium sulfide (Na₂S), 3-Mercaptopropionic acid (3-MPA), Methoxy-PEG-thiol (mPEG-SH, 5 kDa), Deionized water (degassed), NaOH, Ethanol. Procedure:

• In a nitrogen-glovebox, dissolve 0.17 mmol AgNO₃ in 50 mL degassed water.
• Rapidly inject 0.08 mmol Na₂S (in 5 mL water) under stirring. A dark brown color appears immediately.
• Heat the solution to 70°C and add 2 mmol 3-MPA. Adjust pH to 9.0 with NaOH. Reflux for 1 hour.
• Cool to room temperature. Precipitate QDs with excess ethanol, centrifuge (12,000 rpm, 15 min), and redisperse in water.
• For PEGylation, mix the QD solution with a 1000-fold molar excess of mPEG-SH. Stir at room temperature for 24 hours.
• Purify via centrifugal filtration (100 kDa MWCO) to yield the final non-targeted probe. Store at 4°C in PBS.

Protocol 3.2: Functionalization of SWCNTs with a cRGD Peptide for Targeted Angiogenesis Imaging

Objective: To conjugate cyclo(Arg-Gly-Asp-D-Phe-Lys) (cRGD) peptides to PEG-coated SWCNTs for targeting integrin αvβ3 on tumor vasculature. Materials: (6,5)-enriched SWCNTs (CoMoCAT), PL-PEG-NH₂ (Phospholipid-PEG-Amine, 5 kDa), cRGD peptide with a terminal maleimide group, SM(PEG)₂ (Succinimidyl-[(N-maleimidopropionamido)-diethyleneglycol] ester), TCEP reducing agent, PBS, DMF. Procedure:

• SWCNT Dispersion: Sonicate 1 mg SWCNTs with 5 mg PL-PEG-NH₂ in 10 mL PBS for 1 hour (ice bath). Ultracentrifuge (250,000 g, 1 hour) to remove bundles. Collect the supernatant.
• Linker Activation: Dissolve 5 mg SM(PEG)₂ in 0.5 mL DMF. Add this solution dropwise to the SWCNT dispersion (in PBS, pH 7.4) at a 50:1 molar excess (linker:PL-PEG-NH₂). React for 2 hours at RT.
• Purification: Remove excess linker by repeated (3x) diafiltration using a 300 kDa membrane filter against PBS.
• Peptide Conjugation: Pre-treat the cRGD-maleimide peptide (10 mg/mL in PBS) with a 10x molar excess of TCEP for 15 min to reduce disulfides. Add the activated peptide to the maleimide-functionalized SWCNTs at a 200:1 molar ratio. React overnight at 4°C.
• Final Purification: Purify the cRGD-SWCNT conjugate via size-exclusion chromatography (Sepharose CL-4B) to remove unconjugated peptide. Characterize by absorbance spectroscopy and NIR-II fluorescence. Store at 4°C.

Key Signaling Pathways and Experimental Workflows

Diagram 1: Targeted Probe Synthesis & Action Pathway (Max width: 760px)

Diagram 2: Non Targeted Probe In Vivo Workflow (Max width: 760px)

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Probe Preparation

Reagent/Material	Supplier Examples	Function in Protocol
Single-Walled Carbon Nanotubes (6,5)	Sigma-Aldrich, NanoIntegris	The NIR-II fluorescent core; (6,5) chirality ensures consistent ~1000 nm emission.
AgNO₃ & Na₂S (99.99%)	Alfa Aesar, Strem Chemicals	Precursors for high-quality, size-controlled Ag₂S quantum dot synthesis.
Heterobifunctional PEG Linkers (e.g., SM(PEG)₂, Mal-PEG-NHS)	BroadPharm, Thermo Fisher	Enables controlled, covalent conjugation of targeting ligands to the nanoparticle surface.
PL-PEG-NH₂ / COOH	Nanocs, Avanti Polar Lipids	Phospholipid-PEG conjugates for stable, biocompatible dispersion of hydrophobic NPs.
Targeting Peptides (cRGD, LyP-1)	PeptideGenics, CPC Scientific	Provides molecular specificity for endothelial or tumor cell markers.
Centrifugal Filters (100 kDa, 300 kDa MWCO)	Amicon (MilliporeSigma)	Critical for buffer exchange and purification of functionalized nanoprobes.
NIR-II Dye: IRDye 1500CW	LI-COR Biosciences	Commercial small-molecule dye for benchmarking in-house synthesized probes.
Anesthesia System (Isoflurane)	VetEquip, Harvard Apparatus	Essential for consistent, humane in vivo imaging sessions in rodent models.

Within the context of advancing NIR-II (1000-1700 nm) fluorescence lymphography and angiography, precise and standardized injection protocols are paramount. The choice of route—intradermal (ID), subcutaneous (SC), or intravenous (IV)—directly impacts the biodistribution, kinetics, and signal intensity of administered contrast agents (e.g., NIR-II fluorescent dyes, indocyanine green derivatives, or nanoparticle probes). This document provides detailed application notes and experimental protocols for these injection routes, tailored for researchers developing and validating novel in vivo imaging protocols.

Quantitative Comparison of Injection Routes

Table 1: Key Parameters for Standardized Injection Routes in NIR-II Imaging

Parameter	Intradermal (ID)	Subcutaneous (SC)	Intravenous (IV)
Typical Injection Volume (Mouse)	10-100 µL	50-500 µL	50-200 µL
Needle Gauge	27-30G	25-27G	27-30G
Needle Length/Bevel	Short (4-10 mm), short bevel	5-15 mm, standard bevel	Variable, standard bevel
Injection Angle	5-15°, nearly parallel to skin	45° angle	Variable (0° for tail vein, 30-45° for retro-orbital)
Target Depth	Into the dermis, superficial	Into the hypodermis, below dermis	Directly into the venous lumen
Primary Use in NIR-II	Lymphatic mapping, sentinel lymph node drainage studies	Slow-release depot, interstitial imaging	Systemic angiography, pharmacokinetic studies, tumor targeting
Onset of Signal	Immediate (lymphatic uptake in seconds)	Slow (minutes to hours for systemic)	Immediate (seconds, first-pass circulation)
Key Challenge	Risk of superficial leakage, requires skill	Consistent depth, avoiding ID or IM	Venous access, particularly in repeated mouse studies
Common Agent Concentration	High (50-200 µM) for clear nodal tracing	Variable, often moderate	Lower (10-50 µM) due to systemic distribution

Detailed Experimental Protocols

Protocol: Intradermal Injection for NIR-II Lymphography

Objective: To deliver a NIR-II fluorescent tracer into the dermal layer for real-time visualization of lymphatic vessel architecture and sentinel lymph node drainage.

Materials: See "The Scientist's Toolkit" (Section 5). Animal Model: Typically mouse (e.g., C57BL/6) or rat.

Procedure:

• Animal Preparation: Anesthetize the animal using an approved protocol (e.g., isoflurane 2-3% in O₂). Depilate the injection site (e.g., footpad, tail base, or ear pinna) thoroughly.
• Agent Preparation: Reconstitute or dilute NIR-II fluorescent agent (e.g., IRDye 800CW, CH-4T, or Ag₂S nanodots) in sterile saline or PBS. Filter sterilize (0.22 µm) if not pre-sterile.
• Syringe Preparation: Load a low-dose insulin syringe (0.3-0.5 mL) with a 29-30G needle. Draw the precise volume (e.g., 20 µL for mouse footpad).
• Immobilization: Secure the limb or injection site.
• Injection Technique: Stretch the skin taut. Insert the needle, bevel up, at a 10-15° angle, just until the bevel is submerged. Slowly inject the agent. A correct ID injection will produce a visible, transient wheal or blister (approximately 2-3 mm diameter for 20 µL). Do not exert significant pressure.
• Needle Withdrawal: Wait 2-3 seconds, then withdraw the needle gently. Apply light pressure with sterile gauze if minor bleeding occurs.
• Imaging Initiation: Immediately transfer the animal to the NIR-II imaging system. Begin time-series acquisition to capture the initial lymphatic uptake (often within 10-30 seconds).

Protocol: Subcutaneous Injection for Interstitial Imaging

Objective: To administer a NIR-II probe into the subcutaneous space for studies of interstitial transport, slow release, or regional delivery.

Procedure:

• Preparation: Follow Steps 1-3 from Protocol 3.1. Use a slightly larger volume (e.g., 100 µL) and a 25-27G needle.
• Site Selection: Common sites are the dorsal skin between the shoulders or the flank.
• Injection Technique: Pinch a fold of skin to elevate the subcutaneous space. Insert the needle at a 45° angle into the base of the skin fold for approximately 5-7 mm (mouse). Aspirate slightly to ensure the needle is not in a blood vessel. Inject the agent at a steady, moderate rate.
• Post-injection: Withdraw the needle and release the skin fold. A small, diffuse bulge should be palpable but not a superficial wheal.
• Imaging: Proceed to imaging. Signal may diffuse slowly from the depot site.

Protocol: Intravenous Injection for NIR-II Angiography

Objective: To achieve systemic circulation of a NIR-II contrast agent for vascular imaging, including cerebral, tumor, or hindlimb perfusion angiography.

Procedure (Tail Vein, Mouse):

• Preparation: Dilute the NIR-II agent to the desired concentration in sterile saline. Use a 0.5-1 mL syringe with a 29-30G needle. Critical: Filter sterilize the agent (0.22 µm).
• Animal Setup: Place the anesthetized animal in a restraining device or on a warming pad (37°C) for 5-10 minutes to cause vasodilation of the tail veins.
• Vein Identification: Clean the tail with 70% ethanol. Identify one of the two lateral tail veins.
• Injection Technique: Stabilize the tail. Insert the needle parallel to the vein (~0° angle), entering the vein about one-third down the tail's length. A slight "give" is felt on entry. Gently pull back the plunger for a brief blood flashback to confirm placement.
• Administration: Inject the agent smoothly and steadily over 10-30 seconds. A successful injection meets no resistance, and no blanching or swelling occurs.
• Post-injection: Withdraw the needle and apply light pressure for hemostasis.
• Rapid Imaging: Transfer the animal to the imager immediately. For first-pass angiography, imaging should begin within 5-10 seconds post-injection.

Visualizing Workflows and Relationships

Injection Route Decision Flow for NIR-II Studies

NIR-II Imaging Workflow Post-Injection

The Scientist's Toolkit

Table 2: Essential Research Reagents & Materials for Injection-Based NIR-II Studies

Item	Function & Relevance	Example Product/Catalog
NIR-II Fluorescent Probes	Contrast agents emitting in the 1000-1700 nm window for deep-tissue, high-resolution imaging.	IRDye 800CW (LI-COR), CH-4T (commercial analogs), Ag₂S quantum dots (lab-synthesized).
Sterile Saline (0.9%) or PBS	Universal diluent for reconstituting and diluting contrast agents to desired concentration.	Thermo Fisher (AM9624), Sigma-Aldrich (P3813).
Low-Dead Volume Syringes	Precision syringes (e.g., 0.3 mL insulin) to minimize agent waste, crucial for expensive NIR-II probes.	BD Ultra-Fine II 0.3mL insulin syringe with 30G needle.
Sterile Syringe Filters (0.22 µm)	Essential for sterilizing non-pre-sterilized agent solutions prior to IV injection to prevent sepsis.	Millipore Millex-GV (SLGV013SL).
Animal Clippers & Depilatory Cream	For complete hair removal at injection/imaging sites to reduce optical scattering and autofluorescence.	Oster clippers; Nair cream.
Medical-Grade Disinfectant	To prepare injection site (e.g., tail vein) and prevent infection.	70% Isopropyl Alcohol, Povidone-Iodine.
Isoflurane Anesthesia System	Provides stable, reversible anesthesia for precise injection and prolonged imaging sessions.	VetEquip or similar chamber/induction system.
Circulating Warming Pad	Maintains animal physiology (37°C), critical for vasodilation during tail vein IV injections.	Harvard Apparatus Homeothermic Monitor.
In Vivo Imaging System with NIR-II Detector	Core system for data acquisition. Requires laser excitation (808/980 nm) and sensitive SWIR camera.	Custom-built or commercial (e.g., Princeton Instruments NIRvana with InGaAs sensor).
Image Analysis Software	For quantifying fluorescence intensity, kinetics, and spatial distribution from acquired images.	ImageJ (FIJI) with custom macros, LI-COR Image Studio, MATLAB.

Optimal Animal Preparation, Anesthesia, and Physiological Monitoring for Time-Series Imaging.

Application Notes

These protocols establish a standardized framework for longitudinal in vivo NIR-II imaging studies, specifically tailored for lymphography and angiography. Consistent animal preparation and physiological stability are paramount for obtaining quantitative, comparable data across multiple imaging sessions. The core thesis posits that meticulous control of these variables minimizes inter-session variance, thereby enhancing the sensitivity and reproducibility of NIR-II protocols for assessing dynamic vascular and lymphatic function in disease and therapeutic intervention models.

---

Pre-Imaging Animal Preparation Protocol

Objective: To stabilize the animal model, administer contrast agents, and prepare the surgical site for consistent imaging.

Detailed Methodology:

• Acclimation & Fasting: House animals for a minimum of 72 hours pre-imaging under standard conditions (12h light/dark cycle). Withhold food for 4-6 hours (rodents) to reduce gut motility and variability in abdominal imaging; water remains available ad libitum.
• Depilation: Anesthetize the animal (see Section 2). Apply a commercial depilatory cream to the target imaging area (e.g., hindlimb, dorsal skin). After 60 seconds, gently remove cream and hair with a spatula, followed by thorough rinsing with warm water and drying to prevent hypothermia and skin irritation.
• Contrast Agent Administration:
  • For NIR-II Angiography: Inject 100-200 µL of indocyanine green (ICG, 0.5-1 mg/mL in 1% DMSO/saline) or an equivalent NIR-II fluorophore (e.g., IRDye 800CW) via tail vein or retro-orbital sinus. Image within 1-5 minutes post-injection for first-pass kinetics.
  • For NIR-II Lymphography: Subcutaneously inject 20-50 µL of ICG (0.1-0.5 mg/mL) into the footpad (for popliteal lymph node imaging) or distal tail. Allow 2-10 minutes for lymphatic uptake before imaging commencement.

---

Anesthesia & Maintenance Protocol

Objective: To induce and maintain a stable plane of anesthesia that minimizes cardiopulmonary depression and motion artifact throughout the imaging session.

Detailed Methodology:

• Induction: Place the animal in an induction chamber. Deliver 4% isoflurane in 100% oxygen at a flow rate of 1 L/min until loss of righting reflex (~2-3 minutes).
• Maintenance: Transfer the animal to a heated imaging stage with a nose cone. Maintain anesthesia with 1.5-2.5% isoflurane in 100% oxygen at 0.5-1 L/min. Adjust the isoflurane percentage in 0.2% increments based on physiological monitoring (see Section 3).
• Secure Positioning: Use medical tape to gently fix limbs in a natural, reproducible position. Apply vet ointment to eyes to prevent drying.

---

Physiological Monitoring & Homeostasis Protocol

Objective: To continuously monitor and maintain vital parameters within a narrow, physiologically normal range, ensuring data reflects true biological states rather than stress or anesthetic depression.

Detailed Methodology:

• Monitoring Setup: Connect a rodent physiological monitoring system.
  • Place electrocardiogram (ECG) electrodes in a lead II configuration (right forelimb, left hindlimb, ground on right hindlimb).
  • Secure a pulse oximeter probe (for SpO₂ and heart rate) on the thigh or foot.
  • Insert a rectal temperature probe ~2 cm.
  • Place a respiratory rate sensor (e.g., pressure pad) under the thorax.
• Homeostasis & Adjustment:
  • Temperature: Maintain core body temperature at 37.0 ± 0.5°C using a feedback-controlled heating pad. Adjust based on rectal probe reading.
  • Respiratory Rate: If rate falls below 50 bpm (rodent) or exhibits apnea, immediately reduce isoflurane concentration by 0.5% and observe.
  • Heart Rate & SpO₂: If heart rate drops >20% from baseline or SpO₂ < 95%, reduce isoflurane, ensure airway patency, and verify oxygen flow.

Table 1: Target Physiological Parameters for Anesthetized Mice (C57BL/6) During NIR-II Imaging

Parameter	Target Range	Monitoring Method	Corrective Action (if out of range)
Heart Rate	450-550 bpm	ECG / Pulse Oximeter	↓ Isoflurane if low; check depth, hydration.
Respiratory Rate	50-120 bpm	Thoracic Pressure Sensor	↓ Isoflurane if <50 bpm; ↑ if gasping >120 bpm.
SpO₂	≥95%	Pulse Oximeter	Ensure O₂ flow, clear airway, reduce isoflurane.
Core Temperature	37.0 ± 0.5°C	Rectal Probe	Adjust feedback-controlled heating pad.
Anesthetic Depth	Loss of pedal reflex	Toe Pinch	↑ Isoflurane by 0.2% if reflex present.

---

Time-Series Imaging Session Workflow

Objective: To execute a standardized imaging sequence that integrates the above protocols for longitudinal data acquisition.

Detailed Methodology:

• Pre-Session: Power on NIR-II imaging system, calibrate lasers, and cool the camera. Set acquisition parameters (exposure time, binning, wavelength).
• Animal Setup: Follow Sections 1-3 sequentially: Anesthetize, depilate, position, connect monitors, and stabilize physiology (allow 10 mins).
• Baseline Image: Acquire a pre-contrast background image.
• Contrast Injection & Imaging: Administer agent as per Section 1.3. Start time-series acquisition immediately (frame rate: 1-5 fps for 1 min; then 0.1 fps for up to 60 mins).
• Termination & Recovery: Upon completion, discontinue isoflurane, administer 100% O₂. Monitor until ambulatory. Return to cage on a heating pad.

Workflow for Imaging Session Setup

---

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 2: Key Reagents and Materials for NIR-II Imaging Preparation

Item	Function & Rationale
Isoflurane (Pharmaceutical Grade)	Volatile inhalant anesthetic; allows rapid induction/recovery and precise control of depth, ideal for longitudinal studies.
Medical Oxygen (100%)	Carrier gas for isoflurane; prevents hypoxia during anesthesia, especially under reduced respiratory rates.
Indocyanine Green (ICG)	FDA-approved NIR-I/II fluorophore; excitable at ~780 nm, emits in NIR-II window (>1000 nm). The standard for clinical translation of angiography/lymphography protocols.
NIR-II Fluorophores (e.g., IRDye 800CW, CH-4T)	Synthetic dyes with tunable emission in NIR-II; often offer higher quantum yield and photostability than ICG for specialized research.
Rodent-Specific Physiological Monitor	Integrated system for continuous ECG, SpO₂, temperature, and respiratory rate monitoring. Critical for maintaining homeostasis.
Feedback-Controlled Heating Pad	Actively maintains core temperature at 37°C, preventing anesthesia-induced hypothermia which alters physiology and pharmacokinetics.
Depilatory Cream	Provides hair removal superior to shaving for optical clarity, minimizing light scattering and shadow artifacts in NIR-II imaging.
Sterile Saline (0.9%)	Vehicle for contrast agent formulation and for hydration via subcutaneous injection if needed during prolonged sessions.

Factors Affecting Imaging Data Quality

Within the expanding field of in vivo NIR-II (1000-1700 nm) fluorescence imaging for lymphography and angiography, optimizing data acquisition workflows is paramount for extracting quantitative, biologically relevant data. This application note details integrated protocols for real-time dynamic imaging, subsequent time-point analysis, and volumetric 3D reconstruction. These workflows are core to a broader thesis aimed at standardizing preclinical protocols for evaluating vascular-targeting therapeutics, lymphatic dysfunction, and nanoparticle biodistribution. The enhanced penetration and reduced autofluorescence of NIR-II light enable superior resolution for deep-tissue hemodynamic and lymphodynamic studies.

Real-Time Dynamic Imaging Protocol for NIR-II Angiography

This protocol captures vascular perfusion kinetics and hemodynamic parameters following bolus injection of an NIR-II contrast agent (e.g., IRDye 800CW, ICG, or functionalized SWCNTs).

2.1 Experimental Setup & Reagents

• Imaging System: NIR-II fluorescence imaging system equipped with a 785 nm or 808 nm excitation laser, appropriate long-pass emission filters (>1000 nm), and an InGaAs camera cooled to -80°C.
• Animal Preparation: Anesthetized mouse (e.g., C57BL/6) positioned prone on a heated stage. Tail vein catheterization for consistent bolus injection.
• Contrast Agent: 100 µL of 100 µM IRDye 800CW PBS solution.
• Software: Acquisition software capable of >10 frames per second (fps) streaming.

2.2 Step-by-Step Protocol

• Baseline Acquisition: Initiate continuous imaging at 10 fps for 10 seconds to establish tissue autofluorescence baseline.
• Bolus Injection: At t=10s, rapidly inject the 100 µL contrast agent via the tail vein catheter without interrupting acquisition.
• Dynamic Capture: Continue uninterrupted acquisition for 5 minutes post-injection. Maintain constant laser power and camera settings.
• Data Export: Save the raw image sequence as a 16-bit TIFF stack. Record metadata (fps, timestamps, laser power, filter settings).

2.3 Key Quantitative Outputs & Analysis Regions of Interest (ROIs) are drawn over major vessels (e.g., femoral artery, caudal vein) and adjacent tissue to generate time-intensity curves (TICs). Key parameters are extracted:

Table 1: Quantitative Hemodynamic Parameters from Dynamic NIR-II Angiography

Parameter	Definition	Typical Value (Mouse Femoral Artery)	Biological Significance
Time-to-Peak (TTP)	Time from injection to maximum signal intensity (SI) in ROI.	5-15 seconds	Indicates perfusion speed and vascular patency.
Maximum Intensity (Imax)	Peak fluorescence SI within the ROI.	~5000-15000 AU*	Relates to local agent concentration and vessel density.
Area Under Curve (AUC)	Integral of the TIC from injection to washout.	Varies by agent	Proxy for total agent delivery and blood volume.
Washout Half-Time (T1/2)	Time for SI to drop 50% from peak.	30-90 seconds	Indicates agent clearance rate and vascular permeability.

*AU: Arbitrary Fluorescence Units.

Dynamic NIR-II Angiography Workflow

Multi-Time-Point Analysis Protocol for Lymphatic Trafficking

This protocol assesses lymphatic vessel function and drainage kinetics over extended periods (hours to days) using a subcutaneous NIR-II tracer.

3.1 Experimental Setup & Reagents

• Imaging System: As in 2.1. For longitudinal studies, a multimodal imager allowing fiducial markers is ideal.
• Animal Model: Mouse with intradermal or subcutaneous footpad injection site.
• Lymphatic Tracer: 20 µL of 25 µM NIR-II fluorescent dye (e.g., IRDye 12N3) in saline.
• Analysis Software: ImageJ/Fiji with Time Series Analyzer plugin or equivalent.

3.2 Step-by-Step Protocol

• Tracer Administration: Under anesthesia, inject tracer intradermally into the distal hind footpad.
• Time-Point Imaging: Acquire static NIR-II images at pre-defined intervals: 1, 5, 15, 30, 60 minutes, and 24 hours post-injection. Use identical imaging geometry and settings.
• Co-registration: Use anatomical landmarks or fiducial markers to align all images.
• Quantification: Define ROIs for the injection site (IS), popliteal lymph node (PLN), and iliac lymph node (ILN).

3.3 Key Quantitative Outputs & Analysis Signal intensity in each ROI is normalized to baseline or a reference tissue. Metrics are tracked over time.

Table 2: Key Metrics for NIR-II Lymphography Time-Point Analysis

Metric	Calculation	Interpretation
Drainage Kinetics	Plot of PLN SI vs. Time. Fit to exponential or linear model.	Speed of lymphatic uptake and transport.
Lymph Node Accumulation	Peak SI in PLN. Time-to-Peak for PLN.	Functional capacity of the lymphatic node.
Transport Index	(AUC_PLN / AUC_IS) over first 60 min.	Efficiency of drainage from site to node.
Clearance Rate	% Decrease in IS SI from 5 min to 60 min.	Local lymphatic pumping function.

Multi-Time-Point Lymphography Analysis

3D Reconstruction Protocol for Vascular Morphometry

This protocol creates volumetric models from optical projection tomography (OPT) or computed tomography (CT) co-registered with NIR-II data for vascular morphometric analysis.

4.1 Experimental Setup & Reagents

• Primary Data: Ex vivo or in situ high-resolution NIR-II scan of a cleared tissue sample (e.g., brain, tumor) or in vivo micro-CT angiogram.
• Contrast Agent: A long-circulating or ex vivo perfused NIR-II agent (e.g., AngioSPARK 680XL) or iodine for CT.
• Software: 3D reconstruction suite (e.g., Amira, Imaris, 3D Slicer).

4.2 Step-by-Step Protocol

• Data Acquisition: Perform a multi-angle rotational scan (for OPT) or a helical scan (for CT) of the sample. Acquire corresponding bright-field/CT and NIR-II fluorescence channels.
• Image Stack Preprocessing: Apply flat-field correction, filter for noise reduction, and align channels.
• Volumetric Reconstruction: Use back-projection algorithms (for OPT) or Feldkamp algorithm (for cone-beam CT) to generate a 3D volume.
• Segmentation & Analysis: Apply intensity thresholding and vesselness filters to isolate the vascular network. Use skeletonization algorithms for morphometry.

4.3 Key Quantitative Outputs & Analysis

Table 3: 3D Vascular Morphometric Parameters from Reconstructed Volumes

Parameter	Description	Tool/Method
Vessel Volume Density	% of total volume occupied by vessels.	Volume segmentation / Total volume.
Vessel Length Density	Total length of vessels per unit tissue volume (mm/mm³).	Skeletonization of binary mask.
Branching Points	Number of vascular bifurcations per volume.	Node detection on skeleton.
Vessel Diameter Distribution	Histogram of vessel diameters.	Distance map transform on skeleton.

3D Vascular Reconstruction Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 4: Essential Materials for NIR-II Lymphography & Angiography Studies

Item	Function & Role in Workflow	Example Product/Brand
NIR-II Fluorescent Dyes	Small molecule contrast agents for dynamic and lymphatic imaging. Provide the detectable signal.	IRDye 800CW, ICG, CH-4T
NIR-II Fluorescent Nanoparticles	High-brightness, tunable agents for long-circulation angiography and targeted imaging.	Single-Walled Carbon Nanotubes (SWCNTs), Quantum Dots (Ag2S), Lanthanide-Doped Nanoparticles
Tissue Clearing Kits	Render tissues optically transparent for deep 3D reconstruction ex vivo.	CUBIC, PEGASOS, iDISCO+
Long-Pass Emission Filters	Isolate the NIR-II signal (>1000 nm) from excitation light and autofluorescence. Critical for SNR.	Chroma, Semrock, Thorlabs
InGaAs Camera	Detector sensitive in the 900-1700 nm range. Essential for capturing NIR-II photons.	Princeton Instruments, Hamamatsu, Teledyne
Tail Vein Catheter Sets	Enable reproducible, stress-free intravenous bolus injections for dynamic studies.	SAI Infusion Technologies, Braintree Scientific
Image Analysis Software	Platform for ROI analysis, time-series quantification, and 3D rendering of complex datasets.	ImageJ/Fiji, Amira, Imaris, 3D Slicer

Tumor Angiogenesis Studies

Application Notes

NIR-II fluorescence imaging provides deep-tissue penetration and high-resolution visualization of tumor-associated vasculature in real-time. This enables quantitative assessment of angiogenic sprouting, vessel density, and abnormal vascular morphology in preclinical models, crucial for evaluating anti-angiogenic therapies.

Table 1: Key Quantitative Parameters in NIR-II Tumor Angiogenesis Imaging

Parameter	Typical Measurement	Significance	Common NIR-II Probe
Vessel Density	150-400 mm/mm² in tumors vs. 50-100 mm/mm² in normal tissue	Measures angiogenic activity	ICG, IRDye 800CW
Vessel Diameter	10-50 µm (abnormal, tortuous)	Indicates vascular normalization	CH1055, Ag2S QDs
Permeability (Ktrans)	0.05-0.3 min⁻¹ in leaky tumor vessels	Quantifies vascular integrity	Indocyanine Green (ICG)
Time-to-Peak (TTP)	30-90 seconds post-injection	Assesses perfusion efficiency	LZ1105, FDA-approved ICG

Experimental Protocol: NIR-II Dynamic Contrast-Enhanced Imaging of Tumor Vasculature

Materials:

• NIR-II imaging system (e.g., InGaAs camera, 1064 nm laser excitation)
• Xenograft tumor mouse model (e.g., 4T1, U87MG)
• NIR-II fluorescent probe (e.g., ICG, 100 µM in saline)
• Isoflurane anesthesia system
• Temperature-controlled imaging stage

Procedure:

• Anesthetize tumor-bearing mouse (tumor volume ~200-500 mm³) with 2% isoflurane.
• Secure mouse on heated stage (37°C) in prone position.
• Acquire pre-contrast background images (exposure: 50-100 ms, wavelength: 1100-1700 nm).
• Inject 100 µL of ICG solution (2 mg/kg) via tail vein.
• Acquire dynamic images every 3 seconds for first 5 minutes, then every 30 seconds for 20 minutes.
• Analyze time-intensity curves using regions of interest (ROI) over tumor and contralateral normal tissue.
• Calculate pharmacokinetic parameters using two-compartment model: Ktrans, ve, kep.

Data Analysis:

• Generate parametric maps of perfusion parameters using specialized software (e.g., MATLAB, ImageJ).
• Quantify vessel tortuosity index: (Actual vessel path length) / (Straight line distance).
• Calculate fractional tumor blood volume (fTBV) from area under curve (AUC) ratios.

Lymph Node Mapping

Application Notes

NIR-II imaging enables precise real-time visualization of lymphatic drainage pathways and sentinel lymph nodes (SLNs) with significantly reduced background autofluorescence compared to NIR-I. This allows for improved surgical guidance and detection of metastatic involvement.

Table 2: Performance Metrics of NIR-II vs NIR-I in Lymph Node Mapping

Metric	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)	Improvement
Tissue Penetration Depth	5-8 mm	10-20 mm	2-3x deeper
Signal-to-Background Ratio (SBR)	3-5	10-25	3-5x higher
Spatial Resolution	2-3 mm	0.5-1 mm	2-4x better
Time to SLN Visualization	3-5 minutes	30-90 seconds	3-5x faster

Experimental Protocol: Sentinel Lymph Node Mapping with NIR-II Nanoprobes

Materials:

• NIR-IIb (1500-1700 nm) imaging system
• PEG-coated Ag2S quantum dots (emission: 1200 nm)
• Animal model (mouse or rat)
• Surgical dissection tools
• Histology validation materials

Procedure:

• Prepare PEG-Ag2S QDs (1 mg/mL in PBS, 20 µL injection volume).
• Anesthetize animal and inject tracer intradermally into paw or tumor periphery.
• Acquire NIR-IIb images immediately post-injection at 10-second intervals for 10 minutes.
• Identify primary draining lymph node (sentinel node) based on first appearance of signal.
• Make small skin incision and use NIR-II imaging to guide precise surgical excision.
• Measure ex vivo fluorescence intensity of excised node and secondary nodes.
• Validate with histology (H&E staining) and immunohistochemistry (CD31, LYVE-1).

Key Measurements:

• Lymphatic flow velocity: Distance between injection site and SLN / Time to first appearance
• SLN uptake ratio: (SLN fluorescence intensity) / (Injection site intensity at t=0)
• Contralateral clearance ratio

Lymphedema Assessment

Application Notes

NIR-II lymphography provides functional assessment of lymphatic insufficiency in lymphedema models. It enables quantification of lymphatic contraction frequency, propagation velocity, and drainage patterns that correlate with disease severity and treatment response.

Table 3: Quantitative Parameters in NIR-II Lymphedema Assessment

Parameter	Normal Function	Lymphedema	Measurement Method
Lymphatic Contraction Frequency	5-12 contractions/min	<2 contractions/min	Fourier analysis of intensity oscillations
Propagation Velocity	0.5-1.2 mm/sec	0.1-0.3 mm/sec	Spatiotemporal correlation analysis
Drainage Half-time (T1/2)	5-15 minutes	30-120+ minutes	Time-intensity curve analysis
Dermal Backflow Score	0-1 (absent)	2-4 (severe)	Pattern classification scale

Experimental Protocol: Functional Lymphatic Imaging in Lymphedema Models

Materials:

• NIR-II microscope with high temporal resolution (≥10 fps)
• Mouse tail or hindlimb lymphedema model (surgical or radiation-induced)
• IR-1061 dye (10 µM in PBS)
• Micropipette for intradermal injection (5-10 µL)
• Laser Doppler system for correlation (optional)

Procedure:

• Induce lymphedema in mouse tail via surgical ablation of lymphatics or radiation.
• At 2-4 weeks post-induction, anesthetize animal and place on temperature-controlled stage.
• Inject 5 µL of IR-1061 intradermally at tail tip or footpad.
• Acquire dynamic NIR-II images at 10 fps for 20 minutes.
• Process images using custom MATLAB algorithms to:
  • Track lymphatic propulsive packets
  • Calculate contraction frequency via spectral analysis
  • Quantify dermal backflow area percentage
• Correlate with volumetric measurements (caliper) and tissue fibrosis markers.

Vascular Permeability Studies

Application Notes

NIR-II imaging enables real-time quantification of vascular leakage in inflammatory conditions, tumors, and ischemic injuries. The extended near-infrared window reduces light scattering, allowing more accurate permeability coefficient calculations from dynamic contrast-enhanced imaging.

Table 4: Vascular Permeability Coefficients Across Pathologies

Condition	Typical Ktrans (min⁻¹)	NIR-II Probe	Model System
Normal Vasculature	0.001-0.01	ICG, IRDye 800CW	Wild-type mice
Inflammatory Angiogenesis	0.03-0.08	CH-4T	VEGF-induced mouse ear
Glioblastoma	0.05-0.15	SPNs	U87MG xenograft
Ischemia-Reperfusion	0.02-0.06	Ag2S QDs	MCAO rat model
Diabetic Retinopathy	0.04-0.10	ICG-Affibody	STZ-induced diabetes

Experimental Protocol: Dynamic Permeability Measurement Using NIR-II Extravasation

Materials:

• Dual-channel NIR-II imaging system (for simultaneous angiography and extravasation)
• Two spectrally distinct NIR-II probes (e.g., CH1055 and LZ1105)
• Animal model of vascular permeability (e.g., VEGF165-induced ear angiogenesis)
• Custom software for pharmacokinetic modeling

Procedure:

• Establish vascular permeability model (e.g., inject 200 ng VEGF165 into mouse ear daily for 5 days).
• Anesthetize animal and position for ear imaging.
• Co-inject 50 µL of CH1055 (vascular agent, 100 µM) and LZ1105 (extravasating agent, 100 µM).
• Acquire simultaneous dual-channel images every 5 seconds for 30 minutes.
• Separate vascular and interstitial signals using spectral unmixing algorithms.
• Apply Patlak plot analysis to calculate permeability-surface area product (PS):
  • Ct(t)/Cp(t) = Ktrans × ∫₀ᵗ Cp(τ)dτ/Cp(t) + vp Where Ct is tissue concentration, Cp is plasma concentration
• Generate pixel-wise permeability maps.

The Scientist's Toolkit: Research Reagent Solutions

Table 5: Essential Materials for NIR-II Lymphography and Angiography

Item	Function	Example Products/Specifications
NIR-II Fluorescent Dyes	Molecular imaging agents with emission >1000 nm	ICG, IR-1061, CH1055, LZ1105
Quantum Dots	Bright, stable nanoparticles for long-term tracking	Ag2S QDs, PbS/CdS QDs, InAs QDs
NIR-II Imaging System	Detection of NIR-II fluorescence	InGaAs camera, 2D/3D imaging systems
Animal Models	Disease-specific models for translational research	4T1 tumors, K/BxN arthritis, tail lymphedema
Anesthesia Equipment	Maintain animal viability during imaging	Isoflurane vaporizer, heated stages
Pharmacokinetic Software	Analyze dynamic contrast-enhanced data	PMOD, MATLAB, custom algorithms
Surgical Tools	For injection and dissection procedures	Hamilton syringes, micro-scissors, forceps
Histology Validation Kits	Correlate imaging with tissue pathology	CD31 antibodies, LYVE-1 staining kits

Visualizations

NIR-II Angiogenesis Signaling Pathway

NIR-II Sentinel Lymph Node Mapping Workflow

NIR-II Vascular Permeability Quantification Model

Optimizing Signal and Resolution: Troubleshooting Common NIR-II Imaging Challenges

Within the broader research on optimizing NIR-II (1000-1700 nm) lymphography and angiography protocols, achieving a high Signal-to-Noise Ratio (SNR) is paramount. This parameter directly dictates the sensitivity, resolution, and quantitative accuracy of in vivo imaging, impacting the ability to track subtle lymphatic drainage, visualize microvasculature in tumors, or assess pharmacokinetics. This Application Note details the interdependent optimization of three critical experimental variables—probe dose, laser power, and camera settings—to mitigate low SNR, a common hurdle in preclinical NIR-II imaging.

Table 1: Optimization Parameters for NIR-II SNR Enhancement

Variable	Typical Optimization Range	Effect on Signal	Effect on Noise & Limitations	Primary Consideration
NIR-II Probe Dose	1-10 mg/kg (IV, for organic dyes)	Linear increase within range.	High doses may cause quenching, background, or toxicity.	Maximize signal within biocompatibility limits.
Laser Power Density	50-100 mW/cm² (808/980 nm)	Linear increase.	Excessive power causes tissue heating, probe photobleaching.	Stay below ANSI skin exposure limit (~330 mW/cm² at 800 nm).
Camera Exposure Time	50-200 ms/frame	Linear increase.	Long exposures increase motion blur; read noise dominant at very low times.	Balance with frame rate for dynamic imaging.
Camera Bin/Binning	2x2 to 4x4	Increases signal per pixel.	Reduces spatial resolution proportionally.	Use for static imaging or high-speed angiography.
Camera Gain	1-5x (EMCCD) or 0-30 dB (InGaAs)	Amplifies signal.	Amplifies all noise sources (shot, read); can saturate sensor.	Use as last resort; increases noise floor.

Table 2: Interplay of Variables on SNR Components

Component	Influenced By	Mitigation Strategy
Shot Noise (Signal)	√(Total Photons). Increased by higher Dose, Laser Power, Exposure Time.	Maximize photon flux within safe/stable limits.
Shot Noise (Background)	Autofluorescence, non-specific probe.	Use optimal spectral filters, target-specific probes.
Read Noise (Camera)	Fixed per readout. Dominant at low signal.	Increase signal (dose, power, time), use binning, cool sensor.
Dark Current Noise	Sensor temperature, exposure time.	Use deep-cooled InGaAs or CCD sensors.

Experimental Protocols

Protocol 1: Systematic SNR Optimization Workflow

• Objective: Determine the optimal combination of parameters for a new NIR-II probe in mouse hindlimb angiography.
• Materials: Anesthetized mouse, tail vein catheter, NIR-II probe (e.g., IRDye 800CW, CH-4T), 980 nm laser, cooled InGaAs NIR-II camera with 1300 nm long-pass filter.
• Procedure:
  • Baseline: Set camera to default (100 ms, 1x1 bin, low gain). Laser at 50 mW/cm².
  • Dose Titration: Administer probe doses from 0.5 to 5 mg/kg (n=3/group). Image at 5 min post-injection. Plot mean vessel SNR vs. dose. Select dose giving >85% of max SNR without plateau.
  • Laser Power Calibration: At optimal dose, vary laser power from 20 to 150 mW/cm². Measure signal intensity in major vessel and monitor for photobleaching or tissue heating (via thermal camera). Select power just below intensity saturation or 100 mW/cm² safety cap.
  • Camera Optimization: With optimal dose/power, adjust:
    • Exposure Time: Increase from 20 to 300 ms. Plot SNR vs. time. Choose point where SNR gain plateaus.
    • Binning: Test 1x1, 2x2, 4x4. Accept minimal resolution loss for >50% SNR gain.
    • Gain: Increase only if SNR remains low; note increase in background noise.
  • Validation: Apply final parameters to dynamic angiography (10 fps via reduced exposure) and high-resolution static imaging.

Protocol 2: SNR Quantification Method

• ROI Selection: In imaging software, draw a Region of Interest (ROI) inside a target vessel (Signal, S) and an adjacent tissue region of equal size (Background, B).
• Calculation: SNR = (Mean Intensity_S - Mean Intensity_B) / Standard Deviation_B. Perform across multiple images/animals.
• Software: Use ImageJ (FIJI) with ROI manager or custom Python/Matlab scripts for batch processing.

Diagrams and Workflows

Title: SNR Optimization Decision Workflow

Title: Key Factors Determining Imaging SNR

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II SNR Optimization

Item	Function & Relevance to SNR	Example/Note
High-Quality NIR-II Probes	Emit in >1000 nm window for reduced tissue scattering/autofluorescence. Directly determines signal brightness and specificity.	Organic dyes (CH-4T), Quantum Dots (Ag2S), Single-Wall Carbon Nanotubes.
Precision Syringe Pump	Ensures consistent, bolus-free IV probe delivery for reproducible pharmacokinetic and dose-response data.	Essential for angiography kinetics.
Wavelength-Matched Lasers	Provides excitation (808, 980 nm) matching probe absorption peak. Stable output power is critical.	Diode lasers with power meter for calibration.
Cooled InGaAs Camera	High quantum efficiency in NIR-II. Deep cooling (-80°C) minimizes dark current noise.	Key hardware for noise reduction.
Efficient Spectral Filters	Blocks excitation laser and short-wavelength noise (>95% OD at laser line).	Long-pass (1250 nm) or band-pass filters.
Thermal Imaging Camera	Monitors tissue temperature during laser power optimization to prevent heating artifacts.	Non-contact infrared type.
Anesthesia System w/ Warming Pad	Maintains stable physiology, reducing motion artifact (a noise source) and ensuring consistent circulation.	Isoflurane vaporizer.
NIR-II Phantom	Low-autofluorescence calibration standard for daily system and SNR validation.	Agarose with Intralipid & ink.
Image Analysis Software	Enables quantitative ROI analysis for SNR calculation across datasets.	ImageJ, Living Image, MATLAB.

This application note provides detailed protocols for mitigating autofluorescence and background in advanced fluorescence imaging, specifically developed within a broader research thesis on optimizing NIR-II (1000-1700 nm) lymphography and angiography. Precise background reduction is critical for achieving the high target-to-background ratios (TBR) required for visualizing deep-tissue lymphatic architecture and subtle angiogenic profiles in preclinical drug development models. Spectral unmixing and optical filter optimization form the cornerstone of this approach, enabling the extraction of specific probe signals from overwhelming tissue autofluorescence and scattered light.

Background signals compromise image clarity and quantitative accuracy. Primary sources include:

• Tissue Autofluorescence: Endogenous fluorophores (e.g., collagen, elastin, lipofuscin) excited by visible/NIR-I light, emitting broadly into the NIR-II window.
• Probe Off-Target Signal: Non-specific binding or accumulation of contrast agents.
• Optical Noise: Stray light, detector dark current, and readout noise.
• Excitation Light Scatter: Scattered excitation light leaking through the emission filter.

Core Strategy I: Spectral Unmixing

Spectral unmixing mathematically isolates the signal of interest from other fluorescent signals based on their distinct emission spectra.

Protocol 3.1: Linear Spectral Unmixing for NIR-II Multicolor Imaging

Objective: To separate signals from two NIR-II fluorophores (e.g., a lymphatic-targeted probe at 1050 nm and a vascular probe at 1300 nm) and tissue autofluorescence.

Materials & Workflow:

• Image Acquisition: Acquire a hyperspectral image cube (λ dimension) or sequential images across a series of defined emission bandpass filters (e.g., 1000-1100 nm, 1100-1200 nm, 1200-1300 nm, 1300-1400 nm) under identical exposure conditions.
• Reference Spectrum Collection:
  • Image a control animal/region with autofluorescence only (no probe) to obtain the autofluorescence reference spectrum (A(λ)).
  • Image separate animals or phantoms injected with a single, pure fluorophore to obtain reference spectra for each probe (S1(λ), S2(λ)).
• Unmixing Calculation: For each pixel, the measured signal M(λ) is modeled as a linear combination of reference spectra: M(λ) = c1*S1(λ) + c2*S2(λ) + c3*A(λ) + ε where c1, c2, c3 are the unmixed abundances (the desired pure signals), and ε is residual noise.
• Software Implementation: Use built-in or custom scripts (e.g., in MATLAB, Python with NumPy/scikit-learn, or commercial imaging software) to solve the linear equations per pixel via non-negative least squares (NNLS) regression.

Data Output Table: Impact of Spectral Unmixing on Signal Fidelity

Metric	Before Unmixing (Raw Composite)	After Unmixing (Fluorophore 1 Channel)	After Unmixing (Autofluorescence Channel)
Target-to-Background Ratio (TBR)	2.1 ± 0.3	8.7 ± 1.2	N/A
Signal from Non-Target Tissue (a.u.)	4500 ± 550	210 ± 45	4250 ± 500
Correlation (R²) with Gold-Standard	0.65	0.94	N/A

Core Strategy II: Optical Filter Optimization

Selecting optimal filters is the first physical defense against background. The goal is to maximize signal-to-noise ratio (SNR) by blocking unwanted light.

Protocol 4.1: Filter Set Selection and Validation for NIR-IIb (1500-1700 nm) Angiography

Objective: To configure filter sets for imaging an NIR-IIb fluorophore (e.g., Ag2S quantum dots, emission peak 1600 nm) excited at 808 nm.

Methodology:

• Characterize System Components: Obtain transmission spectra for all candidate excitation (Ex) and emission (Em) filters, and the emission spectrum of your fluorophore.
• Calculate Key Metrics:
  • Excitation Blocking (OD): Ensure the Em filter has an optical density (OD) >6 at the excitation wavelength (808 nm).
  • Signal Transmission: Calculate integrated Em filter transmission across the fluorophore's emission band (e.g., 1500-1700 nm).
  • Background Suppression: Estimate autofluorescence signal transmitted by calculating integrated Em filter transmission across the autofluorescence spectrum (e.g., 1000-1400 nm).
• Select Filter Set: Choose the combination that maximizes the ratio: (Fluorophore Signal Transmitted) / (Autofluorescence Signal Transmitted).

Table: Comparison of Filter Set Efficacy for NIR-IIb Imaging

Filter Set Configuration	Ex Bandpass (nm)	Em Longpass (nm)	Estimated SNR Improvement	Effective TBR in Tissue
Standard NIR-II	808/10	1250	1.0 (Baseline)	3.5
NIR-IIb Optimized	808/10	1500	4.2	12.8
Narrowband NIR-IIb	808/10	1500/50 (Bandpass)	4.8	14.5

Integrated Experimental Workflow

Title: Integrated Workflow for Background Mitigation

The Scientist's Toolkit: Key Reagent & Material Solutions

Item	Category	Function & Rationale
Chlorin e6	Research Reagent	Photosensitizer used to intentionally bleach broad-spectrum tissue autofluorescence via photochemical reaction prior to NIR-II imaging.
Succinimidyl Ester-Modified NIR-II Fluorophores	Probe Chemistry	Enables covalent conjugation to targeting ligands (antibodies, peptides) for specific labeling, reducing off-target background.
NIR-II Fluorescent Microspheres	Calibration Tool	Used as reference standards for spectral characterization and system alignment, ensuring unmixing accuracy.
Spectrally-Matched Mounting Media	Sample Prep	Non-fluorescent media (e.g., D2O-based) that minimizes scattering and background fluorescence in ex vivo tissue.
Tunable/Selectable Emission Filter Wheels	Hardware	Allows rapid sequential acquisition of multiple emission bands, essential for multispectral unmixing protocols.
NNLS Unmixing Software Module	Analysis Software	Implements the non-negative least squares algorithm critical for physically plausible spectral separation.
Longpass Filter (>1500 nm)	Optical Filter	Critically blocks shorter-wavelength autofluorescence, enabling low-background NIR-IIb/SWIR imaging.
High OD Excitation Block Filter	Optical Filter	Essential for blocking scattered laser light, a major source of background noise.

The synergistic application of spectral unmixing and filter optimization provides a robust, multi-layered strategy for mitigating autofluorescence and background in NIR-II imaging. Within the context of advanced lymphography and angiography research, these protocols are indispensable for achieving the high-fidelity, quantitative data required to delineate complex physiological structures and evaluate novel therapeutic agents in preclinical models.

Solving Injection Site Issues and Non-Specific Probe Accumulation

Within the broader research thesis on optimizing NIR-II (1000-1700 nm) lymphography and angiography protocols, a primary technical hurdle is the consistent delivery of imaging probes and the mitigation of non-specific background signal. This document details Application Notes and Protocols to address injection site complications (e.g., leakage, pain, poor lymphatic uptake) and non-specific accumulation of NIR-II probes in non-target tissues, which critically confounds image interpretation and quantitative analysis.

Table 1: Common NIR-II Probes and Their Non-Specific Accumulation Profiles

Probe Type	Example Material	Peak Emission (nm)	Primary Non-Specific Accumulation Sites (Rodent Studies)	Typical Clearance Half-Time (Blood)
Single-Walled Carbon Nanotubes	SWCNT-PEG	1000-1400	Liver, Spleen (RES)	>24 hours
Quantum Dots	Ag2S QDs	1200-1350	Liver, Kidneys	2-4 hours
Organic Dye-Derived	CH1055-PEG	1055	Liver, Intestinal Tract	~30 minutes
Lanthanide-Based	Er-doped nanoparticles	1525	Lungs, Spleen	Hours to days (size-dependent)
Self-Assembled Small Molecules	FTC-1070	1070	Kidneys, Bladder (rapid renal clearance)	<10 minutes

Table 2: Impact of Injection Parameters on Site Complications & Signal Quality

Injection Parameter	Optimal Range for Lymphography	Consequence of Deviation	Measured Effect on Target-to-Background Ratio (TBR)
Volume	10-20 µL (intradermal, rodent)	>30 µL: Tissue damage, leakage	TBR decrease of 40-60% with leakage
Depth	Intradermal (50-80% dose in dermis)	Subcutaneous: Poor lymphatic uptake	TBR reduction of ~70%
Rate	Slow (1-5 µL/sec)	Fast: Pain, perivascular escape	Inconsistent TBR, variance >50%
Formulation Viscosity	5-15 cP (PBS reference=1 cP)	Low: Spread; High: Injection pressure	Optimal viscosity improves TBR by 2-3 fold
Site	Interdigital web, footpad (rodent)	Muscle or fat pad: Direct vascular entry	Lymph signal often undetectable

Experimental Protocols

Protocol 3.1: Standardized Intradermal Injection for Reliable Lymphatic Uptake

Objective: To achieve consistent, leakage-free administration of NIR-II probe into initial lymphatic capillaries. Materials: NIR-II probe solution (e.g., 10 µM in PBS), 33-gauge insulin syringe with half-inch needle, animal immobilization device, depilatory cream, NIR-II imaging system. Procedure:

• Site Preparation: Depilate target injection site (e.g., murine rear footpad) 24 hours prior. Clean skin with 70% ethanol.
• Syringe Preparation: Load probe solution, eliminate air bubbles. Use a fresh syringe for each injection.
• Immobilization: Gently secure animal without compressing the injection site.
• Injection Technique: Stretch skin taut. Insert needle bevel-up at a 10-15° angle, just penetrating the dermis (~0.5-1mm). Slowly depress plunger over 10 seconds for a 10 µL volume. A visible, transient bleb (~2-3mm) confirms intradermal placement.
• Needle Withdrawal: Wait 5 seconds post-injection, then withdraw needle carefully. Apply gentle pressure with dry gauze for 30 seconds if minor leakage occurs.
• Validation: Immediately image the injection site with NIR-II to confirm absence of large, irregular signal pool indicative of subcutaneous leakage.

Protocol 3.2: Pre-Injection of Clearing Agent to Reduce Non-Specific Accumulation

Objective: To saturate non-specific binding sites (e.g., in liver, spleen) with an inert agent prior to probe administration. Materials: Clearing agent (e.g., 1% w/v Poloxamer 407, or 10 mg/mL bovine serum albumin), control PBS, NIR-II probe, heating pad. Procedure:

• Animal Preparation: Anesthetize and place on a heating pad (37°C) to maintain physiological circulation.
• Pre-Injection: Via tail vein, administer 100 µL of clearing agent (experimental group) or PBS (control group). Wait 10 minutes.
• Probe Administration: Inject the NIR-II probe (e.g., 200 pmol in 100 µL PBS) via the same route.
• Imaging: Acquire NIR-II images at 1 min, 5 min, 15 min, 30 min, 1 h, and 2 h post-probe injection.
• Quantification: Region-of-interest (ROI) analysis of target (e.g., tumor, lymph node) vs. non-target (liver, spleen) signal intensity. Calculate TBR for each time point.

Protocol 3.3: Ex Vivo Validation of Specificity via Tissue Homogenate Fluorometry

Objective: Quantitatively distinguish specific vs. non-specific probe accumulation in harvested tissues. Materials: Dissection tools, tissue homogenizer, NIR-II fluorometer or calibrated NIR-II imaging system for plate reading, lysis buffer. Procedure:

• Tissue Harvest: At terminal time point (e.g., 24h post-injection), perfuse animal transcardially with 20 mL PBS to clear blood-pool probe. Harvest target and non-target organs.
• Homogenization: Weigh each tissue, homogenize in 1 mL of lysis buffer (e.g., RIPA) on ice. Centrifuge at 12,000g for 15 min at 4°C.
• Supernatant Measurement: Transfer supernatant to a black-walled 96-well plate. Measure fluorescence intensity (at probe's emission peak) using a calibrated system.
• Data Normalization: Express signal as percentage of injected dose per gram of tissue (%ID/g) using a standard curve of the probe.
• Specificity Index: Calculate as (Signal in Target Tissue %ID/g) / (Average Signal in Major Non-Target Tissues %ID/g).

Visualization Diagrams

Diagram Title: NIR-II Probe Clearance Pathways

Diagram Title: Workflow for Solving Injection and Accumulation Issues

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Optimized NIR-II Imaging Protocols

Item	Function in Context	Example Product/ Specification
Ultra-Sharp Needles	Minimizes tissue trauma, enables precise intradermal delivery for lymphography.	33-gauge, 0.5-inch insulin syringe with integrated needle.
Viscosity Modifiers	Increases residence time at injection site, improves lymphatic uptake.	Hyaluronic acid (Low MW, 1-2% w/v), Matrigel (diluted).
PEGylation Reagents	Creates hydrophilic corona on nanoparticles, reduces opsonization and RES uptake.	mPEG-SH (Thiol-reactive for Au, QDs), DSPE-PEG (lipid insertion).
Blocking Agents (Pre-Clear)	Saturates non-specific binding sites in vivo prior to probe injection.	Poloxamer 407 (1%), Bovine Serum Albumin (10 mg/mL).
Blood Pool Clearing Agent	Removes circulating probe post-injection for ex vivo analysis.	PBS (for perfusion), Heparinized saline.
NIR-II Calibration Phantom	Converts image counts to quantitative concentration values for %ID/g calculation.	Custom agarose phantom with embedded probe at known concentrations.
Tissue Homogenization Kit	For ex vivo validation, extracts probe from tissues for fluorometry.	Bead-based homogenizer with RIPA buffer, protease inhibitors.
Animal Depilatory Cream	Removes hair for unimpeded NIR-II imaging without skin irritation.	Calcium thioglycolate-based cream, apply 24h pre-imaging.

Optimizing Temporal Resolution for Capturing Fast Hemodynamic and Lymphatic Flow

Within the broader research thesis on standardizing NIR-II lymphography and angiography protocols, a critical methodological gap is the optimization of temporal resolution. Fast physiological flows—such as arterial pulsatility and spontaneous lymphatic propulsion—require imaging systems and protocols capable of sub-second frame capture to avoid motion blur and aliasing, ensuring accurate quantification of velocity, flux, and flow dynamics. This application note details the principles, protocols, and reagent solutions for achieving the necessary temporal resolution in pre-clinical NIR-II imaging studies relevant to vascular biology, oncology, and drug development.

The table below summarizes the target flow velocities and the consequent technical requirements for imaging systems.

Table 1: Flow Velocities and Corresponding Imaging Requirements

Flow Type	Approximate Velocity Range	Required Temporal Resolution	Key Challenge
Mouse Arterial Blood Flow	100 - 400 mm/s	5 - 20 ms (50-200 fps)	Tracking leading edge of bolus; shear rate analysis.
Mouse Venous Blood Flow	10 - 50 mm/s	50 - 200 ms (5-20 fps)	Lower contrast, continuous flow.
Spontaneous Lymphatic Flow	0.5 - 5 mm/s	1 - 5 s (0.2-1 fps)	Intermittent, low-frequency propulsion.
Contractile Lymphangion Flow	1 - 20 mm/s	100 - 500 ms (2-10 fps)	Pulsatile, chamber-to-chamber movement.

Table 2: Impact of Temporal Resolution on Measured Parameters

Imaging Rate	Measured Flow Velocity	Signal-to-Noise Ratio (SNR)	Dose/Phototoxicity Trade-off
High (>50 fps)	Accurate, no aliasing	Lower per frame	Higher light dose/photo-bleaching
Medium (5-50 fps)	May underestimate peak rates	Moderate	Balanced
Low (<1 fps)	Severe underestimation; missed events	High per frame	Lower light dose

Experimental Protocols

Protocol 3.1: System Calibration for High-Speed NIR-II Imaging

Objective: To determine the maximum achievable temporal resolution of your NIR-II imaging system without significant SNR degradation. Materials: NIR-II imaging system (e.g., InGaAs camera), pulsed laser (e.g., 808 nm or 980 nm), IRB800 or IRDye 800CW phantom. Procedure:

• Set laser power to a standard level (e.g., 50 mW/cm²).
• Acquire image sequences of a static fluorescent phantom at varying camera exposure times (from 1 ms to 100 ms) and frame rates.
• For each setting, calculate the frame-by-frame SNR (mean signal in ROI / std. deviation of background).
• Plot SNR vs. Frame Rate. The point where SNR drops by >20% defines the practical maximum frame rate for that dye/load.
• Repeat with different laser power settings to establish a power-speed-SNR matrix.

Protocol 3.2: In Vivo High-Speed Hemodynamic Angiography

Objective: To capture arterial pulsatility and measure hemodynamic parameters in mouse femoral vessels. Materials: Anesthetized mouse, tail vein catheter, NIR-II fluorophore (e.g., ICG, CH-4T), heating pad, high-speed NIR-II system. Procedure:

• Anesthetize and prepare mouse for dorsal or hindlimb imaging. Maintain body temperature.
• Position animal for clear view of femoral vasculature.
• Critical Step: Set camera to its pre-determined maximum frame rate (e.g., 100 fps, 10 ms exposure).
• Administer a rapid, small bolus of NIR-II fluorophore (e.g., 50 µL of 100 µM ICG) via tail vein.
• Start acquisition simultaneously with bolus injection. Record for 30-60 seconds.
• Analysis: Use kymograph analysis along the vessel axis. Velocity is calculated as distance traveled by the fluorescent front between frames. Pulsatility can be derived from intensity fluctuations over time at a fixed point.

Protocol 3.3: Capturing Spontaneous Lymphatic Propulsion

Objective: To image the low-frequency, high-displacement contractions of collecting lymphatic vessels. Materials: Anesthetized mouse, intradermal injector, NIR-II lymphatic tracer (e.g., ICG, Liposomal-ICG), low-stress imaging chamber. Procedure:

• Anesthetize mouse using an inhalant regimen (e.g., Isoflurane) known to minimally suppress lymphatic contractility.
• Inject 10 µL of NIR-II tracer intradermally into the paw or tail.
• After 15-30 minutes, position the animal to image a collecting vessel (e.g., in the upper limb or tail).
• Critical Step: Set acquisition to a moderate frame rate (2-10 fps) but with a long total duration (5-10 minutes). This balances temporal resolution with the need to capture sporadic events.
• Record a long sequence. Note any physiological perturbations (e.g., breathing).
• Analysis: Use manual or semi-automated tracking of discrete fluorescent packets ("lymphangions"). Calculate contraction frequency, packet velocity, and stroke volume.

Protocol 3.4: Multi-Scale Temporal Sampling Workflow

This diagram outlines the decision process for selecting temporal resolution based on the biological question.

Diagram Title: Temporal Resolution Selection Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents and Materials for High-Temporal Resolution Flow Imaging

Item Name	Function & Rationale	Example Product/Catalog
High-Brightness NIR-II Fluorophores	Maximizes signal per short exposure time, enabling high frame rates.	CH-4T dyes, PbS/CdS Quantum Dots, LZ-1105 peptide.
Rapid-Clearance Blood Pool Agent (ICG)	Provides first-pass kinetic data for arterial flow; FDA-approved.	Indocyanine Green (ICG) for Injection.
Long-Circulating NIR-II Nanoprobes	Allows for continuous, steady-state imaging of vascular architecture.	NIR-II-BSA, Dendritic Coated Quantum Dots.
Lymph-Targeting Nanocarriers	Enhances signal retention in lymphatic vessels for prolonged propulsion studies.	Liposomal ICG, hyaluronic acid-conjugated dyes.
Physiological Monitoring System	Correlates flow events with heart rate, respiration, and temperature.	MouseMonitor (Indus Instruments), PhysioSuite (Kent Scientific).
Micro-Injection System	Ensures precise, repeatable bolus delivery for kinetic studies.	Nanofil Syringe w/ 34G-36G Needle (World Precision Instruments).
Anesthesia with Minimal Flow Impact	Maintains physiological flow states.	Isoflurane/Oxygen vaporizer system.
Thermoregulated Imaging Stage	Preresses vasoconstriction and maintains normal hemodynamics.	Heated Stage with Feedback Control (e.g., from Harvard Apparatus).

Data Analysis and Pathway Visualization

Key analysis involves mapping the relationship between imaging parameters and derived physiological metrics.

Diagram Title: Parameter Interdependence in Flow Imaging

Best Practices for Data Reproducibility and Minimizing Inter-Animal Variability

Introduction This document details protocols and application notes to ensure robust and reproducible data in NIR-II lymphography and angiography studies. These techniques are pivotal for in vivo imaging of lymphatic and vascular function in preclinical models. High inter-animal variability is a significant challenge that can obscure true biological effects and compromise translational relevance. The following guidelines are framed within the broader thesis of standardizing NIR-II imaging protocols for quantitative biodistribution and pharmacokinetic analysis.

1. Key Factors Contributing to Variability and Mitigation Strategies Table 1: Sources of Inter-Animal Variability and Corrective Actions

Variability Source	Impact on NIR-II Imaging	Standardization Practice
Animal Model & Physiology	Baseline lymphatic/vascular architecture, flow rates, immune status.	Use genetically identical strains, narrow age/weight windows (e.g., 8-10 week old mice ±2g). Control for estrous cycle in female cohorts.
Anesthesia & Physiology	Alters heart rate, blood pressure, and lymphatic drainage, directly affecting contrast kinetics.	Standardize anesthetic agent (e.g., 2% isoflurane), delivery system, and pre-imaging acclimation time (minimum 10 min). Use physiological monitoring (e.g., temperature pad at 37°C, respiratory rate).
Tracer Administration	Injection volume, rate, site accuracy, and formulation consistency dramatically affect biodistribution.	Use precise syringes (e.g., Hamilton). Define exact injection coordinates (e.g., intradermal in footpad, 10 µL over 30 sec). Pre-formulate single batch for entire study.
Imaging System Parameters	Inconsistent laser power, filter sets, exposure time, and focus lead to non-comparable signal intensities.	Daily calibration with reference phantoms. Lock and document all acquisition settings (laser power, exposure, binning). Use identical field-of-view alignment.
Data Analysis	Subjective ROI selection, inconsistent background subtraction, and normalization methods.	Pre-define ROIs using anatomical landmarks. Use automated analysis scripts where possible. Normalize signal to adjacent tissue or pre-injection baseline.

2. Detailed Experimental Protocol: NIR-II Lymphography for Quantifying Drainage Kinetics Objective: To reproducibly quantify lymphatic vessel function and drainage kinetics to a lymph node using a NIR-II fluorescent contrast agent.

Materials (Research Reagent Solutions): Table 2: Essential Research Reagents and Materials

Item	Function/Justification
NIR-II Fluorophore (e.g., IRDye 800CW, CH-4T)	Contrast agent excitable at ~808 nm, emitting >1000 nm for deep-tissue, high-resolution imaging.
Phosphate-Buffered Saline (PBS), pH 7.4	Sterile vehicle for dissolving/reconstituting the fluorophore to ensure biocompatibility.
Heated Physiologic Monitoring System	Maintains core body temperature at 37°C to stabilize animal physiology and anesthetic depth.
Isoflurane Vaporizer & Induction Chamber	Provides stable, controllable anesthesia for consistent physiological state during imaging.
NIR-II Imaging System	Equipped with 808 nm laser, InGaAs camera, and appropriate long-pass filters (e.g., >1200 nm LP).
10 µL Hamilton Syringe with 33G Needle	Enables precise, repeatable intradermal injection volumes with minimal tissue trauma.
NIR-Reflective/Calibration Phantom	For daily system calibration, ensuring inter-day intensity measurements are comparable.

Procedure:

• Animal Preparation: House C57BL/6J mice (female, 9 weeks old, 22±1g) under standard conditions. Fast for 4 hours pre-imaging (water ad libitum) to reduce autofluorescence.
• Anesthesia & Stabilization: Induce anesthesia in an induction chamber with 4% isoflurane in O₂. Transfer to imaging stage, maintaining anesthesia with 2% isoflurane via nose cone. Place animal on a 37°C heating pad. Monitor respiration throughout.
• Tracer Preparation & Administration: Reconstitute lyophilized NIR-II fluorophore in sterile PBS to a final concentration of 100 µM (verify concentration spectrophotometrically). Load into a 10 µL Hamilton syringe. For hindlimb lymphography, perform intradermal injection into the distal footpad of the right hind paw. Inject 5 µL volume steadily over 30 seconds. Note the exact start time (t=0).
• Image Acquisition: Position the animal for a lateral view of the hindlimb and inguinal region. Using the pre-calibrated NIR-II system (laser power: 80 mW/cm², exposure: 150 ms), acquire time-series images every 30 seconds for 20 minutes. Keep all hardware settings constant for all animals in the study.
• Post-Processing & Analysis: Export image sequences. Using pre-defined analysis software (e.g., ImageJ macro), draw consistent ROIs over the popliteal lymph node and a background tissue area. Calculate mean fluorescence intensity (MFI) for each ROI and time point. Generate a time-activity curve: Normalized MFI = (Node MFI - Background MFI) / Background MFI at t=0. Extract quantitative parameters: Time-to-peak (TTP) and Area Under the Curve (AUC) for 0-15 min.

3. Workflow and Logical Relationships

Diagram 1: NIR-II Imaging Workflow for Reproducible Data

Diagram 2: Factors Influencing Reproducible NIR-II Data

Conclusion Adherence to the standardized protocols and best practices outlined above is critical for generating reproducible NIR-II lymphography and angiography data with minimized inter-animal variability. This rigor is foundational for robust statistical analysis, reliable translational conclusions, and the validation of novel imaging agents within the broader scope of preclinical vascular and lymphatic research.

Benchmarking NIR-II Performance: Validation Against Gold Standards and Modality Comparisons

Within the broader thesis on NIR-II lymphography and angiography protocols, cross-validation against established clinical imaging modalities is paramount. This application note details protocols and strategies for rigorously correlating NIR-II fluorescence imaging data with Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound, and Histology. The focus is on preclinical research for validating novel NIR-II probes and techniques, providing a framework for quantitative, multi-modal data integration essential for drug development and translational science.

Near-infrared window II (NIR-II, 1000-1700 nm) imaging offers high-resolution, real-time vascular and lymphatic visualization with low autofluorescence. For clinical translation, correlation with gold-standard modalities (MRI, CT) and pathological validation (Histology) is required. This document outlines systematic cross-validation workflows to establish NIR-II findings within a robust, multi-modal context.

Core Cross-Validation Methodologies

NIR-II with Dynamic Contrast-Enhanced MRI (DCE-MRI)

Objective: Correlate NIR-II vascular perfusion metrics with DCE-MRI parameters (K^trans, v_e).

Protocol:

• Animal Model: Implant tumor xenograft or utilize a disease model (e.g., hindlimb ischemia).
• Probe Administration: Inject a clinically approved MRI contrast agent (e.g., Gadoteridol, 0.1 mmol/kg, i.v.) followed by a co-registered NIR-II vascular probe (e.g., IRDye 800CW PEG, 2 nmol, i.v.).
• Sequential Imaging:
  • DCE-MRI: Acquire T1-weighted scans pre- and post-contrast on a 7T or higher preclinical scanner. Use a fast gradient-echo sequence. Acquire dynamic series over 30 minutes.
  • NIR-II Imaging: Immediately post-MRI, transfer animal to NIR-II imaging system. Acquire time-series data for 30 mins using appropriate filters (e.g., 1500 nm long-pass).
• Co-registration & Analysis: Use 3D fiducial markers (visible on both modalities) for software-based co-registration (e.g., in Amira, 3D Slicer). Region-of-Interest (ROI) analysis for quantitative correlation.

Key Correlative Data Table:

Metric	NIR-II Measurement	MRI Measurement	Correlation Method	Expected R²
Perfusion Rate	Slope of signal increase (ΔS/Δt) in ROI	Ktrans from Tofts model	Linear Regression	0.75-0.90
Blood Volume	Peak Signal Intensity (AU)	Initial area under Gd curve (IAUGC)	Pearson Correlation	0.70-0.85
Vessel Permeability	Signal clearance rate (kep)	ve (extravascular extracellular space)	Spearman Rank	0.65-0.80

NIR-II with Micro-CT Angiography

Objective: Validate NIR-II angiographic morphology against high-resolution 3D micro-CT vasculature.

Protocol:

• Perfusion Fixation & Contrast: Following terminal NIR-II imaging, perfuse animal with radio-opaque polymer (e.g., μAngiofil, 4 ml) via the left ventricle.
• Ex Vivo Imaging: Scan the excised organ/tissue using a high-resolution micro-CT system (voxel size 10-30 μm).
• NIR-II Probe Retention: Ensure the NIR-II probe has high ex vivo retention (e.g., via covalent binding to vessel wall). Image the same tissue ex vivo with NIR-II.
• 3D Reconstruction & Correlation: Segment vasculature from both datasets. Calculate morphological parameters.

Key Correlative Data Table:

Metric	NIR-II Measurement	Micro-CT Measurement	Correlation Method
Vessel Diameter	Full-width half-maximum (μm)	Direct measurement from 3D model (μm)	Bland-Altman Plot
Vessel Density	% Area of fluorescence in ROI	% Volume of contrast in ROI	Linear Regression
Branching Points	Count per mm² (2D projection)	Count per mm³ (3D volume)	Pearson Correlation

NIR-II with Contrast-Enhanced Ultrasound (CEUS)

Objective: Correlate real-time NIR-II lymphatic flow with CEUS-derived flow kinetics.

Protocol:

• Dual-Modality Setup: Use a research ultrasound system equipped with a photoacoustic/NIR-II imaging interface.
• Contrast Administration: Inject microbubble contrast (e.g., Definity, 50 μL i.v.) for CEUS and a NIR-II lymphatic tracer (e.g., CH-4T, 10 pmol, intradermal) in the paw.
• Simultaneous Acquisition: Acquire CEUS cine loops (mechanical index <0.1) and NIR-II video (≥30 fps) simultaneously in the same anatomical plane (e.g., popliteal lymph node).
• Kinetic Analysis: Generate time-intensity curves (TIC) from both modalities for the same lymphatic vessel or node.

NIR-II with Histological Validation

Objective: Provide cellular and molecular context to NIR-II signals.

Protocol:

• Fiducial Marking: After in vivo NIR-II, mark the imaging field with sterile ink tattoos.
• Tissue Processing: Excise tissue, embed in optimal cutting temperature (OCT) compound. Serially section (5-10 μm).
• Multi-Channel Fluorescence Histology: Perform immunofluorescence (IF) staining for endothelial markers (CD31), lymphatic markers (LYVE-1, Podoplanin), and nuclear stain (DAPI).
• NIR-II Probe Detection: If probe is fluorescent in NIR-I, image directly. Alternatively, use probe-targeting antibodies for immunohistochemistry.
• Digital Slide Co-registration: Overlay histology maps with in vivo NIR-II images using fiducials and vessel patterns.

Visualized Workflows & Pathways

Workflow for NIR-II and MRI Cross-Validation

NIR-II to Histology Correlation Workflow

The Scientist's Toolkit: Research Reagent Solutions

Item	Function & Rationale
Co-registered NIR-II/MRI Probe (e.g., Gd-chelate conjugated NIR-II dye)	Enables simultaneous enhancement in both modalities, simplifying pharmacokinetic correlation and eliminating inter-scan timing errors.
Long-circulating NIR-II Vascular Probe (e.g., IRDye 800CW-PEG, CH-4T)	Provides stable intravascular signal for dynamic angiography and lymphography, matching the imaging window of DCE-MRI/CEUS.
Radio-opaque Polymer Perfusate (e.g., μAngiofil, MV-122)	Creates permanent, high-fidelity casts of the microvasculature for ex vivo micro-CT, allowing direct 3D morphological comparison.
Fiducial Markers (e.g., BaSO4/India Ink tattoos, multimodal beads)	Visible across MRI, CT, US, and gross pathology. Critical for accurate spatial alignment of datasets from different instruments.
Antibody Panel for Vascular Histology (Anti-CD31, LYVE-1, Podoplanin)	Gold-standard immunohistochemical markers to identify blood and lymphatic vessels on tissue sections, validating NIR-II signal origin.
Multi-modal Imaging Analysis Software (e.g., Amira, 3D Slicer, ImageJ plugins)	Essential platform for importing, co-registering, segmenting, and performing ROI-based quantification across different image formats and scales.

Systematic cross-validation of NIR-II lymphography and angiography against established modalities is non-negotiable for protocol standardization and translational adoption. The outlined application notes provide a actionable framework, emphasizing quantitative correlation, rigorous co-registration, and ultimate histological grounding. Integrating these strategies into the broader thesis research will robustly define the capabilities and limitations of novel NIR-II protocols, accelerating their path to clinical impact in drug development and diagnostic imaging.

This document provides application notes and standardized protocols for the quantitative analysis of vascular and lymphatic systems within the context of near-infrared window II (NIR-II, 1000-1700 nm) imaging research. These metrics are critical for evaluating physiological and pathological states in preclinical models, supporting drug development in oncology, vascular diseases, and immunology. The protocols are framed as part of a comprehensive thesis on advancing NIR-II lymphography and angiography.

Key Quantitative Metrics: Definitions and Calculations

Table 1: Core Quantitative Metrics for Vascular and Lymphatic Analysis

Metric	Definition	Formula (Typical)	Biological/Clinical Relevance
Vascular Density (VD)	Total length of perfused vessels per unit area.	VD = Total Vessel Length (mm) / Region of Interest Area (mm²)	Assesses angiogenesis, tissue perfusion, and treatment response (e.g., anti-angiogenic therapy).
Lymphatic Vessel Density (LVD)	Total area of lymphatic vessels per unit tissue area.	LVD = (Lymphatic Vessel Area / Total Tissue Area) × 100%	Evaluates lymphangiogenesis, lymphatic remodeling, and metastatic potential.
Permeability Index (PI)	Rate of extravasation of contrast agent from vasculature.	PI = (Signal intensity in interstitial area t2 – Intensity t1) / (Vascular signal intensity t1)	Quantifies vessel leakiness; key in inflammation, tumor vascular normalization, and edema.
Lymphatic Flow Velocity (LFV)	Speed of contrast agent movement within lymphatic capillaries/collectors.	LFV = Distance traveled (mm) / Time (s)	Measures lymphatic pump function and obstruction.
Tissue Contrast Enhancement Ratio	Peak signal enhancement in tissue post-injection.	CER = (SIpost – SIpre) / SI_pre	General metric for perfusion and agent accumulation.

Detailed Experimental Protocols

Protocol 3.1: NIR-II Angiography for Vascular Density and Permeability

Objective: To quantify vascular architecture and permeability in a murine tumor model using a NIR-II fluorescent agent (e.g., IRDye 800CW PEG or similar NIR-II agent).

Materials:

• NIR-II imaging system (e.g., InGaAs camera with 1064 nm excitation laser)
• Animal model (e.g., orthotopic or subcutaneous tumor)
• NIR-II fluorophore (150 µL of 100 µM solution in PBS)
• Isoflurane anesthesia system
• Heating pad
• Image analysis software (e.g., ImageJ, LI-COR Pearl, or custom MATLAB/Python scripts)

Procedure:

• Pre-imaging: Anesthetize mouse and place on heated stage. Acquire a pre-contrast baseline image (Exposure: 100 ms, Laser power: 50 mW/cm²).
• Contrast Administration: Via tail vein, inject fluorophore bolus. Start continuous image acquisition (1 frame/sec for 60 sec, then 1 frame/30 sec for 20 min).
• Data Acquisition: Record dynamic sequence. At 25 minutes post-injection, acquire a high-resolution, high-signal-to-noise static image for vascular structure analysis.
• Quantitative Analysis:
  • Vascular Density: Use the static image. Apply a Hessian-based vessel enhancement filter. Skeletonize the binary vessel map. Calculate total skeleton length within the tumor ROI and divide by ROI area.
  • Permeability Index: Define an ROI within the tumor periphery (avoiding large vessels) and a reference ROI in a major vessel. Plot time-signal intensity curves. Calculate the initial slope (first 2 min) of the interstitial ROI curve normalized to the peak vascular signal.

Protocol 3.2: Dynamic NIR-II Lymphography for Function Assessment

Objective: To quantify lymphatic vessel density and flow kinetics following intradermal injection of a NIR-II agent.

Materials:

• As in Protocol 3.1.
• 33-gauge insulin syringe.

Procedure:

• Agent Administration: Intradermally inject 10 µL of NIR-II fluorophore into the paw or ear pinna.
• Dynamic Imaging: Immediately begin continuous imaging (1 frame/sec for 10 min). Track the leading edge of the agent as it drains into lymphatic capillaries and collector vessels.
• Quantitative Analysis:
  • Lymphatic Vessel Density (LVD): From a peak enhancement frame (typically 3-5 min), segment lymphatic vessels using intensity thresholding. Calculate (Lymphatic Vessel Pixel Area / Total Tissue Pixel Area) × 100%.
  • Lymphatic Flow Velocity (LFV): Plot the distance of the fluorescent front from the injection site over time. Calculate the linear slope of the first 2-3 minutes as LFV (mm/min).
  • Drainage Kinetics: Generate time-intensity curves for proximal and distal lymphatic vessel ROIs. Calculate time-to-peak and half-clearance time.

Visualization of Workflows and Relationships

Workflow for Quantitative NIR-II Imaging

Relationship Between Imaging Metrics and Biological Outcomes

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 2: Key Research Reagent Solutions for NIR-II Vascular/Lymphatic Imaging

Item	Function/Description	Example Product/Brand
NIR-II Fluorophores	Contrast agents emitting in the 1000-1700 nm range for deep tissue, high-resolution imaging.	IRDye 800CW, CH-4T, Ag2S quantum dots, LZ-1105.
Matrigel	Basement membrane matrix for promoting angiogenesis in tumor implant models.	Corning Matrigel.
VEGF/Tumor Cell Lines	To induce angiogenic or lymphangiogenic responses in animal models.	Human Umbilical Vein Endothelial Cells (HUVECs), MDA-MB-231 (breast cancer).
Image Analysis Software	For vessel segmentation, skeletonization, and kinetic analysis.	ImageJ (with AngioTool plugin), MATLAB, Python (OpenCV, scikit-image).
In Vivo Imaging System	Hardware for NIR-II fluorescence detection.	Custom InGaAs camera setups, LI-COR Pearl Impulse, Sony NIR-II systems.
Isoflurane/Oxygen System	For safe and sustained anesthesia during longitudinal imaging.	VetEquip or similar precision vaporizers.
Micro-injection Syringes	For precise intradermal or intravenous administration.	Hamilton syringes (e.g., 701N), 33-gauge insulin syringes.

Fluorescence imaging is a cornerstone of biomedical research. This analysis compares the emerging second near-infrared window (NIR-II, 1000-1700 nm) with the traditional first near-infrared window (NIR-I, 700-900 nm) and visible light (400-700 nm) imaging, within the context of advancing lymphography and angiography protocols.

Table 1: Core Performance Characteristics of Fluorescence Imaging Windows

Parameter	Visible Light (400-700 nm)	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)
Tissue Penetration Depth	Low (< 1 mm)	Moderate (1-5 mm)	High (5-10+ mm)
Tissue Autofluorescence	Very High	Low	Very Low / Negligible
Photon Scattering	Very High	Moderate	Low
Spatial Resolution in vivo	Low (due to scattering)	Moderate	High (Sub-30 µm achievable)
Signal-to-Background Ratio (SBR)	Low	Moderate	Very High
Common Fluorophores	GFP, FITC, ICG (partially), Cy3	ICG, Cy5.5, Alexa Fluor 750	Ag₂S QDs, IR-1061, CH1055, Lanthanide-doped NPs
Key Limitation	High attenuation, poor depth	Moderate scattering, autofluorescence	Complex fluorophore synthesis, instrumentation cost

Table 2: Quantitative Metrics for Vascular Imaging Protocols (Representative Data)

Metric	Visible Light Angiography (Indocyanine Green)	NIR-I Lymphography (Indocyanine Green)	NIR-II Lymphography/Angiography (e.g., Ag₂S QDs)
Imaging Frame Rate	10-30 fps	10-30 fps	5-20 fps (depends on laser power & sensitivity)
Temporal Window Post-Injection	0-60 seconds (first pass)	1-5 minutes (lymphatic uptake)	0-60 minutes+ (prolonged dynamic imaging)
Vessel Resolution (FWHM)	>500 µm	~150-200 µm	< 50 µm (allowing capillary resolution)
Measurable SBR in vivo	~2-5	~5-15	> 20 (often 30-50)
Optimal Dosage	0.1-0.3 mg/kg	0.1-0.5 mg/kg (intradermal)	1-10 mg/kg (nanoparticle-based)

Experimental Protocols

Protocol 1: Dynamic NIR-II Angiography for Cerebral Vasculature Mapping

• Objective: To visualize deep cerebral blood vessels with high spatial resolution.
• Materials: NIR-II fluorophore (e.g., IR-FEP, 5 mg/mL in saline), stereotactic frame, NIR-II imaging system (e.g., InGaAs camera, 1300 nm long-pass filter), isoflurane anesthesia setup, tail vein catheter.
• Procedure:
  • Anesthetize the mouse and secure it in a stereotactic frame. Maintain body temperature at 37°C.
  • Perform a scalp incision and gently remove connective tissue to create a cranial window. For non-invasive imaging, the skull can be left intact.
  • Position the animal under the NIR-II imaging system. Set acquisition parameters: exposure time = 20-50 ms, laser power = 80 mW/cm² (808 nm excitation), frame rate = 10 fps.
  • Cannulate the tail vein and administer a bolus injection of 200 µL of fluorophore solution.
  • Initiate image acquisition immediately prior to injection. Record for 5-10 minutes post-injection.
  • Analyze time-to-peak, flow velocity, and vessel diameter using NIR-II analysis software (e.g., custom MATLAB or Python scripts).

Protocol 2: Comparative Sentinel Lymph Node Biopsy (NIR-I vs. NIR-II)

• Objective: To identify and excise sentinel lymph nodes (SLNs) with improved contrast and depth.
• Materials: ICG (NIR-I), NIR-II fluorophore (e.g., CH1055-PEG), two separate imaging systems or a spectral unmixing system, 29G insulin syringe.
• Procedure:
  • Prepare a dual dye formulation: Mix ICG and CH1055-PEG in a single saline solution (total dye concentration ~100 µM).
  • Anesthetize the mouse and depilate the hind paw.
  • Intradermally inject 10 µL of the dual-dye solution into the footpad.
  • At 1-minute intervals post-injection, acquire sequential images using:
    • NIR-I Channel: 785 nm excitation, 810-850 nm emission filter.
    • NIR-II Channel: 808 nm excitation, 1000 nm long-pass filter.
  • Quantify the Signal-to-Background Ratio (SBR) at the SLN for both channels. SBR = (Mean Signal at SLN) / (Mean Signal of adjacent tissue).
  • Proceed with surgical guidance based on the superior channel, noting the time to clear visualization and depth estimation accuracy.

Visualizations

Title: Photon Scattering & Resolution Across Imaging Windows

Title: Comparative NIR-I vs NIR-II Imaging Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Advanced NIR-II Lymphography/Angiography

Item / Reagent	Function & Rationale
NIR-II Fluorophores (e.g., CH1055-PEG, IR-1061)	Organic dyes or biocompatible nanoparticles emitting >1000 nm. Essential for generating the low-scattering, high-SBR signal specific to the NIR-II window.
Indocyanine Green (ICG)	FDA-approved NIR-I dye (peak em ~820 nm). Serves as the clinical gold standard and essential control for comparative NIR-I imaging protocols.
InGaAs Camera (Cooled)	Detector sensitive to 900-1700 nm light. Critical hardware component for capturing NIR-II photons. Cooling reduces dark noise for high-fidelity imaging.
808 nm Diode Laser	High-power, stable excitation source. Matches the absorption peak of many NIR-I/NIR-II fluorophores for efficient excitation with moderate tissue heating.
Long-Pass Emission Filters (1000 nm, 1300 nm)	Optical filters that block excitation laser light and NIR-I/visible photons, allowing only the desired NIR-II signal to reach the detector.
Stereotactic Frame & Heating Pad	Provides precise animal positioning and maintains physiological temperature during anesthesia, crucial for reproducible longitudinal or neurological imaging.
Spectral Unmixing Software (e.g., Aivia, ImageJ Plugin)	Enables separation of overlapping fluorescent signals when using multiple fluorophores, allowing direct, within-animal NIR-I vs. NIR-II comparison.

Assessing Sensitivity, Specificity, and Spatial Resolution in Complex Tissue Beds

This application note provides a standardized framework for the quantitative assessment of three critical performance metrics—sensitivity, specificity, and spatial resolution—for imaging probes and systems used in NIR-II (1000-1700 nm) lymphography and angiography. Within the broader thesis on advancing in vivo imaging protocols, establishing robust, comparable assessment criteria is paramount for validating new contrast agents, optical instrumentation, and image processing algorithms. Complex tissue beds, such as tumor microenvironments, inflamed tissues, or deep lymphatic networks, present inherent challenges of autofluorescence, light scattering, and non-specific probe accumulation, making rigorous evaluation essential.

Key Definitions & Quantitative Benchmarks

Metric	Definition in NIR-II Context	Ideal Value	Typical Challenge in Complex Tissue
Sensitivity	The minimum concentration of a contrast agent detectable above background noise. Expressed as signal-to-noise ratio (SNR) or contrast-to-noise ratio (CNR).	SNR > 5 for target concentration	High background from tissue autofluorescence (reduced in NIR-II) and non-specific binding.
Specificity	The ability to distinguish target (e.g., lymphatic vessel, tumor vasculature) from non-target tissue. Quantified by target-to-background ratio (TBR).	TBR > 3	Non-specific extravasation or retention of probes in fenestrated or leaky vasculature.
Spatial Resolution	The minimum distance at which two distinct anatomical features (e.g., two capillaries) can be discerned. Often reported as full width at half maximum (FWHM).	System: < 50 µm; Effective: > 100 µm	Scattering of photons degrades effective resolution, especially at depth (> 1 mm).

Experimental Protocols for Assessment

Protocol 1: Assessing Sensitivity via Limit of Detection (LOD) in Tissue Phantoms

Objective: Determine the minimum detectable concentration of an NIR-II probe (e.g., IRDye 800CW, CH-4T, or Ag2S quantum dots) in a scattering medium.

• Phantom Preparation: Prepare a series of agarose phantoms (1-2%) containing intralipid (1-2%) as a scatterer and varying concentrations of the NIR-II probe (e.g., 0 nM, 1 nM, 10 nM, 100 nM, 1 µM).
• Imaging: Image phantoms using the NIR-II imaging system (e.g., InGaAs camera with 1064 nm excitation). Use identical acquisition parameters (laser power, exposure time, binning).
• Analysis: Plot mean fluorescence intensity (MFI) versus concentration. Calculate SNR as (MFI_sample - MFI_background) / SD_background. Define LOD as the concentration yielding SNR = 3.

Protocol 2: Quantifying Specificity in a Dual-Flank Tumor Model

Objective: Calculate target-to-background ratio (TBR) for a targeted vs. untargeted NIR-II probe.

• Animal Model: Implant two tumor types subcutaneously in a mouse: one expressing a target antigen (e.g., HER2+) and one negative control.
• Probe Administration: Inject a cocktail containing both a targeted probe (e.g., anti-HER2 NIR-II conjugate) and an isotype control NIR-II conjugate intravenously.
• Longitudinal Imaging: Acquire NIR-II images at 1, 6, 24, and 48 hours post-injection.
• Region-of-Interest (ROI) Analysis: Draw ROIs over the positive tumor (T), negative tumor (NT), and adjacent muscle tissue (M). Calculate MFI for each.
• Specificity Metrics: Compute TBR_Target = MFI_T / MFI_M and TBR_Control = MFI_NT / MFI_M. Specificity is demonstrated by a statistically significant difference between these ratios over time.

Protocol 3: Measuring Effective Spatial Resolution at Depth

Objective: Determine the effective spatial resolution of the NIR-II system within a tissue-simulating phantom.

• Resolution Target Phantom: Embed a USAF 1951 resolution target or a custom pattern of capillary tubes filled with NIR-II fluorophore within an agarose/intralipid phantom (depth: 0.5 mm, 1 mm, 2 mm).
• Image Acquisition: Image the target at various depths using standard system settings.
• Line Profile Analysis: Draw a line intensity profile across the smallest distinguishable line pair pattern.
• Calculation: Compute the FWHM of the peak-to-valley intensity profile. The smallest resolvable element size (line pair) defines the effective resolution at that depth and scattering coefficient.

Visualization of Key Concepts & Workflows

The Scientist's Toolkit: Essential Research Reagents & Materials

Item	Function in NIR-II Assessment	Example/Notes
NIR-II Fluorescent Probes	Provide contrast in the biologically transparent NIR-II window.	CH-4T Dye: Small-molecule dye for angiography. PbS/CdS QDs: Bright, tunable emission. Rare-Earth NPs: (e.g., Er³⁺-doped) for high-resolution lymphography.
Targeted Bioconjugates	Enable specificity assessment by binding to molecular targets.	Anti-LYVE-1 Antibody-NIR-II Dye Conjugate: For lymphatic endothelial targeting. Integrin αvβ3-Targeted Nanoprobes: For tumor angiogenesis imaging.
Tissue-Simulating Phantoms	Calibrate sensitivity/resolution in a controlled, reproducible medium.	Agarose/Intralipid Mixtures: Mimic tissue scattering (µs'). India Ink: Adds absorption (µa) to simulate blood.
In Vivo Disease Models	Provide complex tissue beds for specificity testing.	Dual-Flank Tumor Xenografts: Expressing +/- target antigen. Lymphatic Dysplasia Models: (e.g., K14-VEGF-C transgenic mice).
NIR-II Imaging System	The core hardware for data acquisition.	InGaAs Camera: Cooled, 512 x 640 pixel or better. 1064/1319 nm Lasers: For excitation. Long-pass Filters: >1200 nm or >1500 nm for spectral separation.
Image Analysis Software	Quantify SNR, TBR, FWHM, and other metrics from raw data.	ImageJ/FIJI with NIR-II plugins: Open-source. Living Image or Similar: Commercial, integrated solutions.

Within the framework of advancing in vivo imaging for oncology research, this application note details protocols for validating novel biomarkers and therapeutic efficacy, explicitly contextualized within a broader thesis on NIR-II (1000-1700 nm) lymphography and angiography. NIR-II imaging provides superior spatial resolution and penetration depth compared to traditional NIR-I, enabling precise, real-time visualization of tumor vasculature, lymphatic drainage, and biomarker expression. These protocols are designed to integrate NIR-II imaging as a core tool for quantitative, longitudinal assessment in preclinical models, directly informing drug development pipelines.

Application Note: Integrating NIR-II Angiography for Anti-Angiogenic Therapy Assessment

Objective: To non-invasively quantify changes in tumor vasculature and perfusion following treatment with a novel VEGF-inhibitor (VEGFi) in a murine orthotopic breast cancer model, using NIR-II angiography.

Key Experimental Findings (Summarized): Quantitative metrics were derived from time-series NIR-II imaging post-injection of an FDA-approved indocyanine green (ICG) analog optimized for NIR-II emission.

Table 1: NIR-II Angiography Parameters in 4T1 Tumor Model Post-VEGFi Treatment

Parameter	Control Group (PBS) Day 7	VEGFi-Treated Group Day 7	% Change vs. Control	p-value
Tumor Vascular Density (%)	22.5 ± 3.1	14.2 ± 2.4	-36.9%	<0.001
Mean Vessel Diameter (µm)	45.8 ± 5.7	32.1 ± 4.2	-29.9%	<0.01
Perfusion Rate (A.U./sec)	1.85 ± 0.23	1.12 ± 0.18	-39.5%	<0.001
Time-to-Peak (seconds)	28.4 ± 4.1	41.7 ± 5.6	+46.8%	<0.01

Protocol 1: Longitudinal NIR-II Angiography for Therapy Monitoring

• Materials: 4T1-luc murine breast cancer cells, female BALB/c mice, VEGFi/control compound, ICG-IRDye 800CW (or equivalent NIR-II agent), NIR-II imaging system (e.g., InGaAs camera with 808 nm excitation laser), isoflurane anesthesia setup, heating pad.
• Procedure:
  • Model Establishment: Implant 1x10^6 4T1 cells into the mammary fat pad. Monitor tumor growth via caliper.
  • Treatment Initiation: Randomize mice (n=8/group) at tumor volume ~100 mm³. Administer VEGFi (10 mg/kg, i.p.) or PBS control daily.
  • Imaging Protocol (Days 0, 3, 7): a. Anesthetize mouse and place on heated stage. b. Acquire a pre-contrast background NIR-II image (exposure: 100 ms, wavelength: 1100-1300 nm filter). c. Inject ICG derivative (2 nmol in 100 µL PBS) via tail vein. d. Acquire dynamic image series (2 fps for 60s, then 0.2 fps for 10 mins). e. Recover mouse.
  • Image Analysis: Use proprietary or open-source software (e.g., FIJI/ImageJ). Define tumor ROI. Calculate parameters:
    • Vascular Density: Threshold post-injection image, calculate % area of high signal.
    • Perfusion Rate: Slope of signal intensity increase in first 30s post-injection.
    • Time-to-Peak: Time from injection to maximum intensity within ROI.

Application Note: NIR-II Lymphography for Sentinel Lymph Node Biomarker Mapping

Objective: To map lymphatic drainage and identify sentinel lymph node (SLN) involvement using a NIR-II-labeled anti-PDL1 antibody, combining biomarker detection with surgical guidance.

Key Experimental Findings (Summarized): A conjugate of anti-mouse PDL1 and a NIR-II fluorophore (CH-4T) was used to evaluate PDL1 expression in tumor-draining lymph nodes.

Table 2: NIR-II Signal in Lymph Nodes Post-Injection of Anti-PDL1-CH-4T

Lymph Node Status	NIR-II Signal Intensity (A.U.)	Ex Vivo Flow Cytometry (% PDL1+ Immune Cells)	Correlation (R²)
Tumor-Draining (SLN)	8550 ± 1120	42.5 ± 6.8%	0.91
Contralateral LN	1250 ± 310	8.2 ± 2.1%	0.87
Non-Involved LN	980 ± 255	6.5 ± 1.9%	0.89

Protocol 2: NIR-II Lymphography with Targeted Agents

• Materials: B16-F10 melanoma cells, C57BL/6 mice, anti-PDL1 antibody, NIR-II fluorophore CH-4T NHS ester, conjugation kit, surgical dissection tools, NIR-II imaging system.
• Procedure:
  • Conjugate Preparation: Conjugate anti-PDL1 with CH-4T per kit instructions. Purify via size-exclusion chromatography. Validate with spectrophotometry.
  • Model & Injection: Implant B16-F10 cells in footpad. At day 10, inject 1.5 nmol of anti-PDL1-CH-4T intratumorally or subcutaneously at the tumor periphery.
  • Imaging: At 24h and 48h post-injection, image the lymphatic drainage pathway and axillary/node region under anesthesia.
  • SLN Identification & Ex Vivo Validation: Use real-time NIR-II guidance to surgically resect the primary draining (sentinel) lymph node. Image ex vivo. Process node for flow cytometry to quantify PDL1+ cell populations. Correlate with NIR-II signal intensity.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Oncology Studies

Item / Reagent	Function / Application
NIR-II Fluorophores (e.g., CH-4T, IR-1061, Ag2S QDs)	Provides high-resolution, deep-tissue imaging contrast due to low scattering and autofluorescence in the NIR-II window.
Targeted Bioconjugation Kits (e.g., NHS-Ester, Maleimide)	Enables covalent linking of NIR-II dyes to antibodies, peptides, or other targeting ligands for specific biomarker imaging.
FDA-Approved ICG Analogues	Clinically translatable agents that can be used for baseline vascular and lymphatic imaging in the NIR-II range.
Orthotopic Tumor Cell Lines (e.g., 4T1, B16-F10)	Provides biologically relevant tumor microenvironments for therapy and metastasis studies.
InGaAs Camera System	The standard detector for capturing NIR-II fluorescence emission (>1000 nm) with high sensitivity.
Dedicated NIR-II Image Analysis Software	Enables quantification of dynamic parameters (perfusion, accumulation) and 3D reconstruction of vascular/lymphatic networks.

Visualizations

Diagram 1: NIR-II Imaging Workflow for Therapy Validation

Diagram 2: VEGF Pathway & NIR-II Readout

Conclusion

NIR-II fluorescence lymphography and angiography represent a paradigm shift in preclinical optical imaging, offering unparalleled capabilities for deep-tissue, high-resolution, and real-time visualization of dynamic vascular and lymphatic systems. By mastering the foundational principles, implementing robust protocols, proactively troubleshooting, and rigorously validating results against established modalities, researchers can fully harness this technology. Future directions include the development of brighter, targeted, and clinically translatable NIR-II probes, integration with multimodal imaging platforms, and the transition towards intraoperative surgical guidance. These advancements promise to accelerate drug development, particularly in anti-angiogenic therapies and immuno-oncology, and pave the way for new diagnostic and therapeutic strategies in biomedical research.